


**CUMULATIVE  
SUPPLEMENT 2  
FEBRUARY 2022**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**42nd EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2022**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**42<sup>nd</sup> EDITION**

**Cumulative Supplement  
February 2022**

**CONTENTS**

	<i>PAGE</i>
<b>Contents</b>	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT .....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT .....	vi
1.3 APPLICANT NAME CHANGES .....	vii
1.4 LEVOTHYROXINE SODIUM .....	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
<b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Products Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**42<sup>nd</sup> EDITION**

**CUMULATIVE SUPPLEMENT 2  
FEBRUARY 2022**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
HERITAGE PHARMACEUTICALS INC (HERITAGE PHARMS INC)	HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC (HERITAGE PHARMS)

## 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS
-----	-----------------------------------	-------	-------	---------	---	----

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

---

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).



The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2021</u>	<u>MAR</u> <u>2022</u>	<u>JUN</u> <u>2022</u>	<u>SEP</u> <u>2022</u>	<u>DEC</u> <u>2022</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	21133	2701	(12.8%)		
MULTISOURCE	18432	(87.2%)			

THERAPEUTICALLY EQUIVALENT	18298 (86.6%)
NOT THERAPEUTICALLY EQUIVALENT	134 (0.6%)
EXCEPTIONS <sup>4</sup>	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	13
NUMBER OF APPLICANTS	1190

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABIRATERONE ACETATE

TABLET; ORAL  
 YONSA

>A>	+	SUN PHARM	125MG	N210308	001	May 22, 2018	Feb CAHN
>D>	+	SUN PHARMA GLOBAL	125MG	N210308	001	May 22, 2018	Feb CAHN

ABROCITINIB

TABLET; ORAL  
 CIBINQO

+	PFIZER	50MG	N213871	001	Jan 14, 2022	Jan NEWA
+		100MG	N213871	002	Jan 14, 2022	Jan NEWA
+		200MG	N213871	003	Jan 14, 2022	Jan NEWA

ACETAMINOPHEN

SOLUTION; INTRAVENOUS  
 ACETAMINOPHEN

>D>	AP	SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Feb CHRS
>A>	AP	!	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Feb CHRS
OFIRMEV							
>D>	AP	+	MALLINCKRODT HOSP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010
>A>		+	@	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB	HIKMA	300MG; 50MG; 40MG; 30MG	A215138	002	Jan 26, 2022	Jan NEWA
AB		325MG; 50MG; 40MG; 30MG	A215138	001	Jan 26, 2022	Jan NEWA
AB	LGM PHARMA	300MG; 50MG; 40MG; 30MG	A076560	002	Jul 19, 2012	Jan CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>A>	@	CHARTWELL	300MG; 15MG	A089997	001	Dec 28, 1994	Feb CAHN
>A>	@		300MG; 30MG	A089998	001	Dec 28, 1994	Feb CAHN
>A>	@		300MG; 60MG	A089999	001	Dec 28, 1994	Feb CAHN
>D>	@	WATSON LABS	300MG; 15MG	A089997	001	Dec 28, 1994	Feb CAHN
>D>	@		300MG; 30MG	A089998	001	Dec 28, 1994	Feb CAHN
>D>	@		300MG; 60MG	A089999	001	Dec 28, 1994	Feb CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

>A>	@	CHARTWELL	325MG; 7.5MG	A040248	001	Apr 28, 2000	Feb CAHN
>A>	@		325MG; 10MG	A040248	002	Apr 28, 2000	Feb CAHN
>D>	@	WATSON LABS	325MG; 7.5MG	A040248	001	Apr 28, 2000	Feb CAHN
>D>	@		325MG; 10MG	A040248	002	Apr 28, 2000	Feb CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP	ASPEN	6GM/30ML (200MG/ML)	A213693	001	Feb 03, 2022	Jan NEWA	
>D>	AP	EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Feb DISC
>A>	@		6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Feb DISC
>A>	AP	INDOCO	6GM/30ML (200MG/ML)	A215620	001	Feb 23, 2022	Feb NEWA

ALBUTEROL SULFATE

TABLET; ORAL

ALBUTEROL SULFATE

>A>	@	CHARTWELL RX	EQ 4MG BASE	A072151	002	Dec 05, 1989	Feb CMS1
-----	---	--------------	-------------	---------	-----	--------------	----------

ALLOPURINOL

INJECTABLE; INJECTION

ALLOPURINOL

AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A212363	001	Jan 26, 2022	Jan NEWA
----	------------------	--------------------	---------	-----	--------------	----------

TABLET; ORAL

ALLOPURINOL

>A>	AB	HARMAN FINOCHEM	100MG	A214443	001	Mar 07, 2022	Feb NEWA
>A>	AB		300MG	A214443	002	Mar 07, 2022	Feb NEWA

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL  
AMANTADINE HYDROCHLORIDE

>A> AB STRIDES PHARMA 100MG A211354 001 Feb 18, 2022 Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL  
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

AB MICRO LABS EQ 12.5MG BASE;5MG A211925 001 Feb 02, 2022 Jan NEWA  
 AB EQ 25MG BASE;10MG A211925 002 Feb 02, 2022 Jan NEWA  
 AB MYLAN PHARMS INC EQ 12.5MG BASE;5MG A071297 002 Dec 10, 1986 Jan CTEC  
 AB ! EQ 25MG BASE;10MG A071297 001 Dec 10, 1986 Jan CTEC

AMLODIPINE BESYLATE

>A> SOLUTION;ORAL  
 >A> NORLIQVA  
 >A> +! CMP DEV LLC EQ 1MG BASE/ML N214439 001 Feb 24, 2022 Feb NEWA  
 TABLET;ORAL  
 AMLODIPINE BESYLATE  
 @ CHARTWELL RX EQ 2.5MG BASE A076859 001 Sep 10, 2007 Jan CAHN  
 @ EQ 5MG BASE A076859 002 Sep 10, 2007 Jan CAHN  
 @ EQ 10MG BASE A076859 003 Sep 10, 2007 Jan CAHN  
 NORVASC  
 AB + VIATRIS EQ 2.5MG BASE N019787 001 Jul 31, 1992 Jan CAHN  
 AB + EQ 5MG BASE N019787 002 Jul 31, 1992 Jan CAHN  
 AB +! EQ 10MG BASE N019787 003 Jul 31, 1992 Jan CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB TEVA PHARMS USA 3.125MG;3.125MG;3.125MG;3.125MG A210876 001 Jan 31, 2022 Jan NEWA  
 AB 6.25MG;6.25MG;6.25MG;6.25MG A210876 002 Jan 31, 2022 Jan NEWA  
 AB 9.375MG;9.375MG;9.375MG;9.375MG A210876 003 Jan 31, 2022 Jan NEWA  
 AB 12.5MG;12.5MG;12.5MG;12.5MG A210876 004 Jan 31, 2022 Jan NEWA

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS  
APOKYN

>D> +! MDD US 30MG/3ML (10MG/ML) N021264 002 Apr 20, 2004 Feb CFTG  
 >A> AP +! 30MG/3ML (10MG/ML) N021264 002 Apr 20, 2004 Feb CFTG  
 >A> APOMORPHINE HYDROCHLORIDE  
 >A> AP SAGE CHEMS 30MG/3ML (10MG/ML) A212025 001 Feb 23, 2022 Feb NFTG

APREMILAST

TABLET;ORAL  
APREMILAST

@ AMNEAL 10MG A211782 001 Jun 30, 2021 Jan DISC  
 @ 20MG A211782 002 Jun 30, 2021 Jan DISC  
 @ 30MG A211782 003 Jun 30, 2021 Jan DISC

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION  
ARFORMOTEROL TARTRATE

AN LUPIN EQ 0.015MG BASE/2ML A213068 001 Feb 07, 2022 Jan NEWA  
 >A> AN VISTAPHARM EQ 0.015MG BASE/2ML A214736 001 Mar 02, 2022 Feb NEWA

ARTESUNATE

POWDER;INTRAVENOUS  
ARTESUNATE

>D> +! AMIVAS 110MG/VIAL N213036 001 May 26, 2020 Feb CAHN  
 >A> +! 110MG/VIAL N213036 001 May 26, 2020 Feb CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS  
M.V.I. PEDIATRIC

+ @ HOSPIRA 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL N018920 001 Sep 21, 2000 Jan DISC  
 ;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;  
 17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4M  
 G/VIAL;EQ 1.2MG  
 BASE/VIAL;0.7MG/VIAL;7MG/VIAL

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; INTRAVENOUS

M.V.I. ADULT

+ @	HOSPIRA	200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIAL; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL; 10MG/VIAL; 0.15MG/VIAL	N021625	001	Jan 30, 2004	Jan DISC
-----	---------	---	---------	-----	--------------	----------

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+ @	HOSPIRA	200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0.15MG/5ML	N021643	001	Feb 18, 2004	Jan DISC
-----	---------	--	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@	MAYNE PHARMA INC	325MG; 50MG; 40MG; 30MG	A203335	001	Oct 30, 2015	Jan DISC
---	------------------	-------------------------	---------	-----	--------------	----------

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AB	HETERO LABS LTD III	EQ 150MG BASE	A212278	001	Feb 02, 2022	Jan NEWA
AB		EQ 200MG BASE	A212278	002	Feb 02, 2022	Jan NEWA
AB		EQ 300MG BASE	A212278	003	Feb 02, 2022	Jan NEWA

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AP	AMNEAL	0.5MG/5ML (0.1MG/ML)	A215342	001	Jan 26, 2022	Jan NEWA
AP	+! HOSPIRA	0.5MG/5ML (0.1MG/ML)	N021146	001	Jul 09, 2001	Jan CMFD

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	MAYNE PHARMA INC	0.025MG; 2.5MG	A210789	001	Jun 03, 2020	Jan DISC
---	------------------	----------------	---------	-----	--------------	----------

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+!	MMT	2.1MG/0.7ML; 600MG/2ML	N021983	001	Sep 28, 2006	Jan CAHN
----	-----	------------------------	---------	-----	--------------	----------

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP	AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022	Jan NEWA
----	--------	------------	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

@	AMNEAL	0.2055MG/SPRAY	A208199	001	Dec 15, 2017	Jan DISC
---	--------	----------------	---------	-----	--------------	----------

BACLOFEN

GRANULES; ORAL

LYVISPAH

>A>	+	AMNEAL	5MG/PACKET	N215422	001	Nov 22, 2021	Feb CAHN
>A>	+		10MG/PACKET	N215422	002	Nov 22, 2021	Feb CAHN
>A>	+!		20MG/PACKET	N215422	003	Nov 22, 2021	Feb CAHN
>D>	+	SAOL THERAPS RES LTD	5MG/PACKET	N215422	001	Nov 22, 2021	Feb CAHN
>D>	+		10MG/PACKET	N215422	002	Nov 22, 2021	Feb CAHN
>D>	+!		20MG/PACKET	N215422	003	Nov 22, 2021	Feb CAHN

INJECTABLE; INTRATHECAL

LIORESAL

>A>	AP	+!	AMNEAL	0.05MG/ML	N020075	003	Nov 07, 1996	Feb CAHN
>A>	AP	+!		0.5MG/ML	N020075	001	Jun 17, 1992	Feb CAHN
>A>	AP	+!		2MG/ML	N020075	002	Jun 17, 1992	Feb CAHN
>D>	AP	+!	SAOL THERAPS RES LTD	0.05MG/ML	N020075	003	Nov 07, 1996	Feb CAHN
>D>	AP	+!		0.5MG/ML	N020075	001	Jun 17, 1992	Feb CAHN
>D>	AP	+!		2MG/ML	N020075	002	Jun 17, 1992	Feb CAHN

	SUSPENSION; ORAL						
>A>	FLEQSUVY						
>A>	+!	AZURITY	25MG/5ML	N215602	001	Feb 04, 2022	Feb NEWA
	TABLET; ORAL						
	BACLOFEN						
AB		MANKIND PHARMA	5MG	A215885	001	Jan 25, 2022	Jan NEWA
AB			10MG	A215885	002	Jan 25, 2022	Jan NEWA
AB			20MG	A215885	003	Jan 25, 2022	Jan NEWA
	<u>BENZONATATE</u>						
	CAPSULE; ORAL						
	BENZONATATE						
AA		ACELLA	100MG	A091310	001	Jan 16, 2015	Jan CAHN
AA			200MG	A091310	002	Jan 16, 2015	Jan CAHN
AA	!	THEPHARMANETWORK LLC	100MG	A040627	002	Mar 30, 2007	Jan CMS1
AA	!		150MG	A040627	003	Sep 24, 2014	Jan CMS1
	<u>BENZOYL PEROXIDE; TRETINOIN</u>						
	CREAM; TOPICAL						
	TWYNEO						
>A>	+ @	GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021	Feb CAHN
>D>	+ @	SOL-GEL TECHNOLOGIES	3%;0.1%	N214902	001	Jul 26, 2021	Feb CAHN
	+ @		3%;0.1%	N214902	001	Jul 26, 2021	Jan DISC
	<u>BETAINE</u>						
	FOR SOLUTION; ORAL						
	BETAINE						
AB		LUKARE MEDICAL LLC	1GM/SCOOPFUL	A210508	001	Jan 28, 2022	Jan NEWA
	<u>BETAMETHASONE DIPROPIONATE</u>						
	OINTMENT; TOPICAL						
	BETAMETHASONE DIPROPIONATE						
>A>	AB	TASMAN PHARMA	EQ 0.05% BASE	A215186	001	Feb 18, 2022	Feb NEWA
	<u>BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE</u>						
	TABLET; ORAL						
	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE						
AB		GLENMARK PHARMS LTD	2.5MG;6.25MG	A215995	001	Jan 26, 2022	Jan NEWA
AB			5MG;6.25MG	A215995	002	Jan 26, 2022	Jan NEWA
AB			10MG;6.25MG	A215995	003	Jan 26, 2022	Jan NEWA
	<u>BRIMONIDINE TARTRATE</u>						
	SOLUTION/DROPS; OPHTHALMIC						
	BRIMONIDINE TARTRATE						
AT		APOTEX	0.15%	A078479	001	Jan 31, 2022	Jan NEWA
	<u>BROMFENAC SODIUM</u>						
	SOLUTION/DROPS; OPHTHALMIC						
	BROMFENAC SODIUM						
>D>	@	NOVITIUM PHARMA	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Feb CAHN
>A>	@	VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Feb CAHN
	<u>BUDESONIDE</u>						
	CAPSULE, DELAYED RELEASE; ORAL						
	BUDESONIDE						
	@	NATCO	3MG	A206724	001	Nov 23, 2016	Jan CAHN
	<u>BUMETANIDE</u>						
	INJECTABLE; INJECTION						
	BUMETANIDE						
>D>	@	ATHENEX INC	0.25MG/ML	A074441	001	Jan 27, 1995	Feb CMFD
>A>	AP		0.25MG/ML	A074441	001	Jan 27, 1995	Feb CMFD
	<u>BUPIVACAINE HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	BUPIVACAINE HYDROCHLORIDE						
>D>	@	MYLAN ASI	0.25%	A091503	001	Oct 18, 2011	Feb CAHN
>D>	@		0.5%	A091503	002	Oct 18, 2011	Feb CAHN
>A>	@	STERISCIENCE	0.25%	A091503	001	Oct 18, 2011	Feb CAHN
>A>	@		0.5%	A091503	002	Oct 18, 2011	Feb CAHN

INJECTABLE; INJECTIONBUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	@ MYLAN ASI	0.25%	A091487	002	Oct 18, 2011	Feb CAHN
>D>	@	0.5%	A091487	001	Oct 18, 2011	Feb CAHN
>D>	@	0.75%	A091487	003	Oct 18, 2011	Feb CAHN
>A>	@ STERISCIENCE	0.25%	A091487	002	Oct 18, 2011	Feb CAHN
>A>	@	0.5%	A091487	001	Oct 18, 2011	Feb CAHN
>A>	@	0.75%	A091487	003	Oct 18, 2011	Feb CAHN

BUPRENORPHINE HYDROCHLORIDE

## FILM; BUCCAL

## BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jan CTEC
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jan CTEC
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jan CTEC
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jan CTEC
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jan CTEC
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jan CTEC
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jan CTEC

BUPRENORPHINE HYDROCHLORIDE

@	ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jan DISC
@		EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jan DISC
@		EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jan DISC
@		EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jan DISC
@		EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jan DISC
@		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jan DISC
@		EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jan DISC

BUPROPION HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB3	GRANULES	150MG	A215568	001	Feb 02, 2022	Jan NEWA
AB3		300MG	A215568	002	Feb 02, 2022	Jan NEWA
>A>	AB3 WOCKHARDT LTD	300MG	A202189	002	Jan 28, 2022	Feb NEWA

BUSPIRONE HYDROCHLORIDE

## TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Feb CHRS
>A>	AB	!	15MG	A202557	004	Dec 30, 2014	Feb CHRS
>D>	AB	! MYLAN	7.5MG	A075467	002	Mar 28, 2001	Feb DISC
>A>	AB	@	7.5MG	A075467	002	Mar 28, 2001	Feb DISC
>D>	AB	! TEVA	15MG	A075022	003	Feb 28, 2002	Feb CHRS
>A>	AB		15MG	A075022	003	Feb 28, 2002	Feb CHRS

CAFFEINE CITRATE

## SOLUTION; ORAL

## CAF CIT

+	@ HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jan DISC	
AA	!	EXELA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Jan CHRS

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## SOLUTION; PERFUSION, CARDIAC

## CARDIOPLEGIC IN PLASTIC CONTAINER

>A>	AT	FRESENIUS KABI USA	17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML	A214623	001	Feb 18, 2022	Feb NEWA
-----	----	--------------------	---	---------	-----	--------------	----------

CARBAMAZEPINE

## TABLET; ORAL

CARBAMAZEPINE

>D>	AB	VG YAAN	200MG	A214328	001	Aug 16, 2021	Feb DISC
>A>	AB	@	200MG	A214328	001	Aug 16, 2021	Feb DISC

CARBIDOPA; ENTACAPONE; LEVODOPA

## TABLET; ORAL

## CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	RISING	12.5MG; 200MG; 50MG	A213212	001	Jan 25, 2022	Jan NEWA
AB		18.75MG; 200MG; 75MG	A213212	002	Jan 25, 2022	Jan NEWA
AB		25MG; 200MG; 100MG	A213212	003	Jan 25, 2022	Jan NEWA
AB		31.25MG; 200MG; 125MG	A213212	004	Jan 25, 2022	Jan NEWA
AB		37.5MG; 200MG; 150MG	A213212	005	Jan 25, 2022	Jan NEWA



TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE							
AB	STALEVO 125	50MG;200MG;200MG	A213212	006	Jan 25, 2022	Jan	NEWA
AB	+ ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Jan	CTEC
AB	STALEVO 200						
AB	+! ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Jan	CTEC
AB	STALEVO 50						
AB	+! ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Jan	CTEC
AB	STALEVO 75						
AB	+ ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Jan	CTEC

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION							
CARBOPROST TROMETHAMINE							
AP	AMNEAL	EQ 0.25MG BASE/ML	A215337	001	Jan 27, 2022	Jan	NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION							
CEFEPIME HYDROCHLORIDE							
AP	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Jan	CMFD
AP		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Jan	CMFD

CEFUROXIME SODIUM

INJECTABLE; INJECTION							
ZINACEF							
>A>	AP	+! PAI HOLDINGS PHARM	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN
>A>	AP	+!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN
>D>	AP	+! TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN
>D>	AP	+!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN
INJECTABLE; INTRAMUSCULAR, INTRAVENOUS							
ZINACEF							
>A>	AB	+! PAI HOLDINGS PHARM	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb CAHN
>D>	AB	+! TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb CAHN

CELECOXIB

CAPSULE; ORAL							
CELECOXIB							
>D>	AB	UNICHEM	50MG	A213301	001	Jan 12, 2021	Feb DISC
>A>		@	50MG	A213301	001	Jan 12, 2021	Feb DISC
>D>	AB		100MG	A213301	002	Jan 12, 2021	Feb DISC
>A>		@	100MG	A213301	002	Jan 12, 2021	Feb DISC
>D>	AB		200MG	A213301	003	Jan 12, 2021	Feb DISC
>A>		@	200MG	A213301	003	Jan 12, 2021	Feb DISC
>D>	AB		400MG	A213301	004	Jan 12, 2021	Feb DISC
>A>		@	400MG	A213301	004	Jan 12, 2021	Feb DISC

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL							
LIBRIUM							
AB	+ VALEANT PHARM INTL	5MG	A085461	001		Jan	CRLD
AB	+	10MG	A085472	001		Jan	CRLD

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL							
TUSSICAPS							
>D>		ECR PHARMA	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007	Feb DISC
>A>		@	EQ 4MG MALEATE;EQ 5MG BITARTRATE	A077273	002	Sep 24, 2007	Feb DISC
>D>		!	EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007	Feb DISC
>A>		@	EQ 8MG MALEATE;EQ 10MG BITARTRATE	A077273	001	Sep 24, 2007	Feb DISC

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL							
CHLORPROMAZINE HYDROCHLORIDE							
AB	MSN	25MG	A214827	001	Jan 27, 2022	Jan	NEWA
AB		50MG	A214827	002	Jan 27, 2022	Jan	NEWA
AB		100MG	A214827	003	Jan 27, 2022	Jan	NEWA
AB		200MG	A214827	004	Jan 27, 2022	Jan	NEWA

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB	CHARTWELL RX	25MG	A211063	001	Feb 26, 2019	Jan CAHN
AB		50MG	A211063	002	Feb 26, 2019	Jan CAHN
AB	INVENTIA	25MG	A211320	001	Feb 09, 2022	Jan NEWA
AB		50MG	A211320	002	Feb 09, 2022	Jan NEWA
AB	SUNNY	25MG	A209068	001	Jan 25, 2022	Jan NEWA
AB		50MG	A209068	002	Jan 25, 2022	Jan NEWA
>A>	AB	TAGI	A212878	001	Feb 24, 2022	Feb NEWA
>A>	AB		A212875	001	Feb 24, 2022	Feb NEWA

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

AB	UPSHER SMITH LABS	EQ 4GM RESIN/PACKET	A214877	001	Jan 21, 2022	Jan NEWA
AB		EQ 4GM RESIN/SCOOPFUL	A214877	002	Jan 21, 2022	Jan NEWA

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

>D>	UNIV TX MD ANDERSON	4-100mCi/ML	A205690	001	Oct 29, 2015	Feb DISC
>A>	@	4-100mCi/ML	A205690	001	Oct 29, 2015	Feb DISC

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ CHARTWELL RX 200MG  
 @ 300MG  
 @ 400MG  
 @ 800MG

A074100	001	Jan 31, 1995	Jan CAHN
A074100	002	Jan 31, 1995	Jan CAHN
A074100	003	Jan 31, 1995	Jan CAHN
A074100	004	Jan 31, 1995	Jan CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL

CINACALCET HYDROCHLORIDE

>D>	AB	AMNEAL PHARMS	30MG	A204364	001	Dec 02, 2021	Feb DISC
>A>	@		30MG	A204364	001	Dec 02, 2021	Feb DISC
>D>	AB		60MG	A204364	002	Dec 02, 2021	Feb DISC
>A>	@		60MG	A204364	002	Dec 02, 2021	Feb DISC
>D>	AB		90MG	A204364	003	Dec 02, 2021	Feb DISC
>A>	@		90MG	A204364	003	Dec 02, 2021	Feb DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ AIPING PHARM INC EQ 250MG BASE  
 @ EQ 500MG BASE  
 @ EQ 750MG BASE

A076593	002	Jun 09, 2004	Jan CAHN
A076593	003	Jun 09, 2004	Jan CAHN
A076593	004	Jun 09, 2004	Jan CAHN

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

+! ALMATICA EQ 30MG BASE

N215428	001	Jan 31, 2022	Jan NEWA
---------	-----	--------------	----------

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

AB	ALEMBIC PHARMS LTD	250MG
AB		500MG

A210459	001	Jan 31, 2022	Jan NEWA
A210459	002	Jan 31, 2022	Jan NEWA

CLINDAMYCIN PHOSPHATE

LOTION;TOPICAL

CLINDAMYCIN PHOSPHATE

AB	ENCUBE	EQ 1% BASE
----	--------	------------

A215607	001	Jan 18, 2022	Jan NEWA
---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

>D>	AB	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Feb CTEC
>A>	AB1		1.2%;0.025%	A202564	001	Jun 12, 2015	Feb CTEC
>A>	AB2	SOLARIS PHARMA CORP	1.2%;0.025%	A212845	001	Feb 10, 2022	Feb NETG

A202564	001	Jun 12, 2015	Feb CTEC
A202564	001	Jun 12, 2015	Feb CTEC
A212845	001	Feb 10, 2022	Feb NETG

GEL;TOPICAL  
VELTIN

>D>	BX	+!	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb	CFTG
>A>	AB2	+!		1.2%;0.025%	N050803	001	Jul 16, 2010	Feb	CFTG

ZIANA

>D>	AB	+!	BAUSCH	1.2%;0.025%	N050802	001	Nov 07, 2006	Feb	CTEC
>A>	AB1	+!		1.2%;0.025%	N050802	001	Nov 07, 2006	Feb	CTEC

CLOBAZAM

TABLET;ORAL  
CLOBAZAM

>D>		@	MSN	10MG	A213404	001	May 11, 2021	Feb	CMFD
>A>	AB			10MG	A213404	001	May 11, 2021	Feb	CMFD
>D>		@		20MG	A213404	002	May 11, 2021	Feb	CMFD
>A>	AB			20MG	A213404	002	May 11, 2021	Feb	CMFD

CLOBETASOL PROPIONATE

SOLUTION;TOPICAL  
CLOBETASOL PROPIONATE

>A>	AT		SOLARIS PHARMA CORP	0.05%	A211240	001	Feb 17, 2022	Feb	NEWA
>D>	AT		TOLMAR	0.05%	A076977	001	Aug 05, 2005	Feb	DISC
>A>		@		0.05%	A076977	001	Aug 05, 2005	Feb	DISC

CLONIDINE

TABLET, EXTENDED RELEASE;ORAL  
NEXICLON XR

>D>		@	ATHENA	EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Feb	CMFD
>A>				EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Feb	CMFD
		@		EQ 0.17MG BASE	N022500	001	Dec 03, 2009	Jan	CAHN
		@		EQ 0.26MG BASE	N022500	002	Dec 03, 2009	Jan	CAHN

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
CLONIDINE HYDROCHLORIDE

>D>	AB1		MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018	Feb	DISC
>A>		@		0.1MG	A210680	001	Apr 30, 2018	Feb	DISC

COLCHICINE

TABLET;ORAL  
COLCHICINE

>D>	AB		PAR PHARM INC	0.6MG	A203976	001	Aug 12, 2021	Feb	DISC
>A>		@		0.6MG	A203976	001	Aug 12, 2021	Feb	DISC

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL  
COLESEVELAM HYDROCHLORIDE

	AB		SPH	625MG	A213456	001	Jan 21, 2022	Jan	NEWA
--	----	--	-----	-------	---------	-----	--------------	-----	------

COLESTIPOL HYDROCHLORIDE

TABLET;ORAL  
COLESTIPOL HYDROCHLORIDE

>A>	AB		ZYDUS PHARMS	1GM	A215223	001	Mar 10, 2022	Feb	NEWA
-----	----	--	--------------	-----	---------	-----	--------------	-----	------

CYCLOSPORINE

EMULSION;OPHTHALMIC  
CYCLOSPORINE

	AB		MYLAN	0.05%	A205894	001	Feb 02, 2022	Jan	NFTG
--	----	--	-------	-------	---------	-----	--------------	-----	------

RESTASIS

	AB	+!	ALLERGAN	0.05%	N050790	001	Dec 23, 2002	Jan	CFTG
--	----	----	----------	-------	---------	-----	--------------	-----	------

SOLUTION;ORAL  
CYCLOSPORINE

>D>	AB1		MAYNE PHARMA	100MG/ML	A065054	001	Dec 18, 2001	Feb	DISC
>A>		@		100MG/ML	A065054	001	Dec 18, 2001	Feb	DISC

CYTARABINE

INJECTABLE;INJECTION  
CYTARABINE

>A>	AP		HONG KONG	20MG/ML	A208485	001	Feb 28, 2022	Feb	NEWA
-----	----	--	-----------	---------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN

		TABLET;ORAL					
>A>		DAPAGLIFLOZIN					
>A>	AB	ZYDUS PHARMS	5MG	A211582	001	Feb 22, 2022	Feb NFTG
>A>	AB		10MG	A211582	002	Feb 22, 2022	Feb NFTG
		FARXIGA					
>D>	+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb CFTG
>A>	AB		5MG	N202293	001	Jan 08, 2014	Feb CFTG
>D>			10MG	N202293	002	Jan 08, 2014	Feb CFTG
>A>	AB		10MG	N202293	002	Jan 08, 2014	Feb CFTG

DAPSONE

		GEL;TOPICAL					
		DAPSONE					
AB		MYLAN	7.5%	A213847	001	Feb 04, 2022	Jan NEWA
>A>	AB	TORRENT	7.5%	A214722	001	Feb 10, 2022	Feb NEWA
		TABLET;ORAL					
		DAPSONE					
		@ VIRTUS PHARMS	25MG	A204074	001	May 10, 2016	Jan DISC
		@	100MG	A204074	002	May 10, 2016	Jan DISC

DAPTOMYCIN

		POWDER;INTRAVENOUS						
		DAPZURA RT						
		+!	BAXTER HLTHCARE CORP	500MG/VIAL	N213645	001	Jan 25, 2022	Jan NEWA

DEFERASIROX

		GRANULE;ORAL					
		DEFERASIROX					
>A>	AB	CIPLA	90MG	A215026	001	Feb 23, 2022	Feb NEWA
>A>	AB		180MG	A215026	002	Feb 23, 2022	Feb NEWA
>A>	AB		360MG	A215026	003	Feb 23, 2022	Feb NEWA

DEFERIPRONE

		TABLET;ORAL					
		DEFERIPRONE					
AB		HIKMA	1GM	A213239	002	Feb 08, 2022	Jan NFTG
		FERRIPROX					
AB	+	CHIESI	1GM	N021825	002	Jul 25, 2019	Jan CFTG

DESOGESTREL; ETHINYL ESTRADIOL

		TABLET;ORAL-28					
		DESOGESTREL AND ETHINYL ESTRADIOL					
		@ MAYNE PHARMA	0.15MG,N/A;0.02MG,0.01MG	A076916	001	Dec 29, 2008	Jan DISC
		@	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	A077182	001	Jan 24, 2006	Jan DISC

DESVENLAFAXINE FUMARATE

		TABLET, EXTENDED RELEASE;ORAL					
		DESVENLAFAXINE					
>A>	+	@ SUN PHARM	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CAHN
>A>		@	EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CAHN
>D>	+	@ SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CAHN
>D>		@	EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CAHN

DEXAMETHASONE

		TABLET;ORAL					
		DEXAMETHASONE					
BP	+	HIKMA	0.5MG	A084611	001		Jan CRLD

DEXAMETHASONE SODIUM PHOSPHATE

		INJECTABLE;INJECTION					
		DEXAMETHASONE SODIUM PHOSPHATE					
>D>	AP	!	FRESENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001	Feb CRLD
>A>	AP	+!		EQ 4MG PHOSPHATE/ML	A084916	001	Feb CRLD

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC  
TOBRAMYCIN AND DEXAMETHASONE

>A> AB PADAGIS US 0.1%;0.3% A212715 001 Feb 11, 2022 Feb NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DEXMEDETOMIDINE HYDROCHLORIDE

>D> AP PIRAMAL CRITICAL EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A214794 001 Sep 03, 2021 Feb DISC  
>A> @ EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A214794 001 Sep 03, 2021 Feb DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL  
DEXTROAMPHETAMINE SULFATE

>D> AB MAYNE PHARMA 5MG A076137 001 Jan 18, 2002 Feb DISC  
>A> @ 5MG A076137 001 Jan 18, 2002 Feb DISC  
>D> AB 10MG A076137 002 Jan 18, 2002 Feb DISC  
>A> @ 10MG A076137 002 Jan 18, 2002 Feb DISC  
>D> AB 15MG A076137 003 Jan 18, 2002 Feb DISC  
>A> @ 15MG A076137 003 Jan 18, 2002 Feb DISC

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

ARBOR PHARMS LLC 2.5MG A090533 001 Oct 25, 2011 Jan CTEC  
7.5MG A090533 003 Oct 25, 2011 Jan CTEC  
15MG A090533 005 Oct 25, 2011 Jan CTEC  
20MG A090533 006 Oct 25, 2011 Jan CTEC  
30MG A090533 007 Oct 25, 2011 Jan CTEC  
@ WINDER LABS LLC 2.5MG A212160 001 Jun 07, 2021 Jan DISC  
@ 5MG A212160 002 Jun 07, 2021 Jan DISC  
@ 7.5MG A212160 003 Jun 07, 2021 Jan DISC  
@ 10MG A212160 004 Jun 07, 2021 Jan DISC  
@ 15MG A212160 005 Jun 07, 2021 Jan DISC  
@ 20MG A212160 006 Jun 07, 2021 Jan DISC  
@ 30MG A212160 007 Jun 07, 2021 Jan DISC

DICLOFENAC POTASSIUM

FOR SOLUTION;ORAL  
DICLOFENAC POTASSIUM

>A> AB ANNORA PHARMA 50MG A215375 001 Mar 04, 2022 Feb NEWA

DICYCLOMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DICYCLOMINE HYDROCHLORIDE

>D> AP GENE YORK PHARMS 10MG/ML A212058 001 Apr 26, 2019 Feb DISC  
>A> @ 10MG/ML A212058 001 Apr 26, 2019 Feb DISC

DIGOXIN

TABLET;ORAL

DIGOXIN

AB AUROBINDO PHARMA LTD 0.0625MG A214982 001 Feb 08, 2022 Jan NFTG  
AB 0.125MG A214982 002 Feb 08, 2022 Jan NEWA  
AB 0.25MG A214982 003 Feb 08, 2022 Jan NEWA  
LANOXIN  
AB + CONCORDIA 0.0625MG N020405 001 Sep 30, 1997 Jan CFTG

DILTIAZEM HYDROCHLORIDE

>D> SOLUTION; INTRAVENOUS  
>D> DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%  
>D> +! EXELA PHARMA 125MG/125ML (1MG/ML) N215252 001 Oct 28, 2021 Feb DISC  
>A> + @ 125MG/125ML (1MG/ML) N215252 001 Oct 28, 2021 Feb DISC  
>D> +! 250MG/250ML (1MG/ML) N215252 002 Oct 28, 2021 Feb DISC  
>A> + @ 250MG/250ML (1MG/ML) N215252 002 Oct 28, 2021 Feb DISC

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

>D> @ MAYNE PHARMA EQ 100MG BASE A070173 001 May 31, 1985 Feb CMFD  
>A> AB EQ 100MG BASE A070173 001 May 31, 1985 Feb CMFD  
>D> @ EQ 150MG BASE A070173 002 May 31, 1985 Feb CMFD  
>A> AB EQ 150MG BASE A070173 002 May 31, 1985 Feb CMFD

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL  
DIVALPROEX SODIUM

>A>	AB	UNICHEM	EQ 250MG VALPROIC ACID	A214643	001	Feb 25, 2022	Feb NEWA
>A>	AB		EQ 500MG VALPROIC ACID	A214643	002	Feb 25, 2022	Feb NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE

AT		GLAND PHARMA LTD	EQ 2% BASE	A215660	001	Jan 27, 2022	Jan NEWA
----	--	------------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT		MICRO LABS	EQ 2% BASE;EQ 0.5% BASE	A215936	001	Jan 25, 2022	Jan NEWA
----	--	------------	-------------------------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET;ORAL  
CARDURA

AB	+	VIATRIS	EQ 1MG BASE	N019668	001	Nov 02, 1990	Jan CAHN
AB	+		EQ 2MG BASE	N019668	002	Nov 02, 1990	Jan CAHN
AB	+		EQ 4MG BASE	N019668	003	Nov 02, 1990	Jan CAHN
AB	+		EQ 8MG BASE	N019668	004	Nov 02, 1990	Jan CAHN

DOXAZOSIN MESYLATE

	@	CHARTWELL RX	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan CAHN
	@		EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan CAHN
	@		EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan CAHN
	@		EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

CARDURA XL

+		VIATRIS	EQ 4MG BASE	N021269	001	Feb 22, 2005	Jan CAHN
+	!		EQ 8MG BASE	N021269	002	Feb 22, 2005	Jan CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

>A>	AB	EPIC PHARMA LLC	EQ 50MG BASE	A210675	004	Mar 03, 2022	Feb NEWA
>A>	AB		EQ 75MG BASE	A210675	005	Mar 03, 2022	Feb NEWA
AB		MANKIND PHARMA	EQ 10MG BASE	A215710	001	Feb 09, 2022	Jan NEWA
AB			EQ 25MG BASE	A215710	002	Feb 09, 2022	Jan NEWA
AB			EQ 50MG BASE	A215710	003	Feb 09, 2022	Jan NEWA
AB			EQ 75MG BASE	A215710	004	Feb 09, 2022	Jan NEWA
AB			EQ 100MG BASE	A215710	005	Feb 09, 2022	Jan NEWA

TABLET;ORAL

DOXEPIIN HYDROCHLORIDE

	@	STRIDES PHARMA	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan CAHN
	@		EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP		EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Jan NEWA
AP			4MCG/2ML (2MCG/ML)	A213717	002	Jan 24, 2022	Jan NEWA

DOXYCYCLINE

CAPSULE;ORAL

MONODOX

>A>	AB	+	CHARTWELL RX	EQ 150MG BASE	N050641	004	Feb 17, 2022	Feb NEWA
-----	----	---	--------------	---------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

TABLET;ORAL

DOXYCYCLINE HYCLATE

	@	EMCURE PHARMS LTD	EQ 100MG BASE	A209969	001	Nov 09, 2018	Jan DISC
--	---	-------------------	---------------	---------	-----	--------------	----------

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

>D>	+	DUCHESNAY	20MG;20MG	N209661	001	Nov 07, 2016	Feb CFTG
>A>	AB	+	20MG;20MG	N209661	001	Nov 07, 2016	Feb CFTG

TABLET, EXTENDED RELEASE;ORAL

>A> DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE  
 >A> AB ACTAVIS LABS FL INC 20MG;20MG A212472 001 Mar 01, 2022 Feb NFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
 DRIZALMA SPRINKLE

>A> + SUN PHARM EQ 20MG BASE N212516 001 Jul 19, 2019 Feb CAHN  
 >A> + EQ 30MG BASE N212516 002 Jul 19, 2019 Feb CAHN  
 >A> + EQ 40MG BASE N212516 003 Jul 19, 2019 Feb CAHN  
 >A> +! EQ 60MG BASE N212516 004 Jul 19, 2019 Feb CAHN  
 >D> + SUN PHARMA GLOBAL EQ 20MG BASE N212516 001 Jul 19, 2019 Feb CAHN  
 >D> + EQ 30MG BASE N212516 002 Jul 19, 2019 Feb CAHN  
 >D> + EQ 40MG BASE N212516 003 Jul 19, 2019 Feb CAHN  
 >D> +! EQ 60MG BASE N212516 004 Jul 19, 2019 Feb CAHN

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB HETERO LABS LTD V 600MG;200MG;300MG A203053 001 Jan 24, 2022 Jan NEWA

EFINACONAZOLE

SOLUTION;TOPICAL  
 EFINACONAZOLE

>A> AB LUPIN LTD 10% A212169 001 Mar 02, 2022 Feb NEWA

EFLORNITHINE HYDROCHLORIDE

>D> CREAM;TOPICAL  
 >D> VANIQA  
 >D> +! SKINMEDICA 13.9% N021145 001 Jul 27, 2000 Feb DISC  
 >A> + @ 13.9% N021145 001 Jul 27, 2000 Feb DISC

ELIGLUSTAT TARTRATE

CAPSULE;ORAL  
 ELIGLUSTAT TARTRATE

>A> AB AIZANT EQ 84MG BASE A212463 001 Sep 08, 2021 Feb CAHN  
 >D> AB APPCO EQ 84MG BASE A212463 001 Sep 08, 2021 Feb CAHN

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL  
 DESCOVY  
 + GILEAD SCIENCES INC 120MG;EQ 15MG BASE

N208215 002 Jan 07, 2022 Jan NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL  
 ENALAPRIL MALEATE

>A> AB ANNORA PHARMA 1MG/ML A214467 001 Feb 24, 2022 Feb NEWA

ENALAPRILAT

INJECTABLE;INJECTION  
 ENALAPRILAT

AP ! HIKMA FARMACEUTICA 1.25MG/ML A078687 001 Dec 23, 2008 Jan CHRS  
 AP HOSPIRA 1.25MG/ML A075458 001 Aug 22, 2000 Jan CHRS

ENZALUTAMIDE

CAPSULE;ORAL  
 ENZALUTAMIDE

>D> AB ACTAVIS LABS FL INC 40MG A209614 001 May 14, 2021 Feb DISC  
 >A> @ 40MG A209614 001 May 14, 2021 Feb DISC  
 XTANDI  
 >D> AB +! ASTELLAS 40MG N203415 001 Aug 31, 2012 Feb CTEC  
 >A> +! 40MG N203415 001 Aug 31, 2012 Feb CTEC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS  
 EPHEDRINE SULFATE

>D> + @ ENDO VENTURES 50MG/10ML (5MG/ML) N213994 001 Oct 16, 2020 Feb CMFD  
 >A> +! 50MG/10ML (5MG/ML) N213994 001 Oct 16, 2020 Feb CMFD  
 >A> AP GLAND PHARMA LTD 50MG/ML (50MG/ML) A216146 001 Feb 25, 2022 Feb NEWA

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
LIGNOSPAN FORTE

>D>	!	DEPROCO	EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985	Feb CRLD
>A>	+		EQ 0.02MG BASE/ML;2%	A088389	001	Jan 22, 1985	Feb CRLD
		LIGNOSPAN STANDARD					
	+	DEPROCO	EQ 0.01MG BASE/ML;2%	A088390	001	Jan 22, 1985	Jan CRLD

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION  
ERYTHROMYCIN LACTOBIONATE

>A>	AP	NEXUS PHARMS	EQ 500MG BASE/VIAL	A215290	001	Feb 14, 2022	Feb NEWA
-----	----	--------------	--------------------	---------	-----	--------------	----------

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS  
ESOMEPRAZOLE SODIUM

>A>	AP	HAINAN POLY	EQ 40MG BASE/VIAL	A215732	001	Feb 10, 2022	Feb NEWA
>A>		@ SUN PHARM	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Feb CAHN
>A>	AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Feb CAHN
>D>		@ SUN PHARMA GLOBAL	EQ 20MG BASE/VIAL	A200882	001	Mar 18, 2013	Feb CAHN
>D>	AP		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	Feb CAHN

ESTRADIOL

TABLET; ORAL  
ESTRADIOL

>D>	AB	MAYNE PHARMA	0.5MG	A040114	003	Mar 14, 1996	Feb DISC
>A>		@	0.5MG	A040114	003	Mar 14, 1996	Feb DISC
>D>	AB		1MG	A040114	001	Mar 14, 1996	Feb DISC
>A>		@	1MG	A040114	001	Mar 14, 1996	Feb DISC
>D>	AB		2MG	A040114	002	Mar 14, 1996	Feb DISC
>A>		@	2MG	A040114	002	Mar 14, 1996	Feb DISC

ESZOPICLONE

TABLET; ORAL  
ESZOPICLONE

		@ CHARTWELL RX	1MG	A091165	001	Jul 14, 2011	Jan CAHN
		@	2MG	A091165	002	Jul 14, 2011	Jan CAHN
		@	3MG	A091165	003	Jul 14, 2011	Jan CAHN

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28  
ZOVIA 1/35E-28

		@ MAYNE PHARMA	0.035MG;1MG	A072721	001	Dec 30, 1991	Jan DISC
--	--	----------------	-------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28  
NORETHINDRONE AND ETHINYL ESTRADIOL

		@ MAYNE PHARMA	0.035MG;0.5MG	A070686	001	Jan 29, 1987	Jan DISC
--	--	----------------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21  
MICROGESTIN 1.5/30

		@ MAYNE PHARMA	0.03MG;1.5MG	A075548	002	Jul 30, 2003	Jan DISC
--	--	----------------	--------------	---------	-----	--------------	----------

		@ MAYNE PHARMA	0.02MG;1MG	A075647	002	Jul 30, 2003	Jan DISC
--	--	----------------	------------	---------	-----	--------------	----------

TABLET; ORAL-28  
MICROGESTIN FE 1.5/30

		@ MAYNE PHARMA	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Jan DISC
--	--	----------------	--------------	---------	-----	--------------	----------

		@ MAYNE PHARMA	0.02MG;1MG	A075647	001	Feb 05, 2001	Jan DISC
--	--	----------------	------------	---------	-----	--------------	----------

		@ MAYNE PHARMA	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076629	001	Mar 18, 2010	Jan DISC
--	--	----------------	-----------------------------------	---------	-----	--------------	----------

>A>	AB	MYLAN	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb CMFD
-----	----	-------	-----------------------------------	---------	-----	--------------	----------

>D>		@ MYLAN LABS LTD	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018	Feb CMFD
-----	--	------------------	-----------------------------------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL  
FINZALA

	AB	TEVA PHARMS USA INC	0.02MG;1MG	A210087	001	Apr 07, 2020	Jan CMFD
--	----	---------------------	------------	---------	-----	--------------	----------

		@ AMNEAL PHARMS	0.02MG;1MG	A207514	001	Sep 11, 2017	Jan DISC
--	--	-----------------	------------	---------	-----	--------------	----------



ETONOGESTREL

IMPLANT; IMPLANTATION

IMPLANON

	@ ORGANON	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jan	CAHN
--	-----------	--------------	---------	-----	--------------	-----	------

NEXPLANON

	+! ORGANON	68MG/IMPLANT	N021529	002	May 31, 2011	Jan	CAHN
--	------------	--------------	---------	-----	--------------	-----	------

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE

>A>	@ AKORN	10MG/ML	A076324	001	Nov 27, 2002	Feb	CAHN
-----	---------	---------	---------	-----	--------------	-----	------

>D>	@ APOTEX INC	10MG/ML	A076324	001	Nov 27, 2002	Feb	CAHN
-----	--------------	---------	---------	-----	--------------	-----	------

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

>A>	@ AKORN	10MG/ML	A076322	001	Nov 27, 2002	Feb	CAHN
-----	---------	---------	---------	-----	--------------	-----	------

>D>	@ APOTEX INC	10MG/ML	A076322	001	Nov 27, 2002	Feb	CAHN
-----	--------------	---------	---------	-----	--------------	-----	------

FERRIC CARBOXYMALTOS

SOLUTION; INTRAVENOUS

INJECTAFER

>A>	+! AM REAGENT	100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022	Feb	NEWA
-----	---------------	-------------------------------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

CAPSULE; ORAL

ALLEGRA

	@ CHATTEM SANOFI	60MG	N020625	001	Jul 25, 1996	Jan	CAHN
--	------------------	------	---------	-----	--------------	-----	------

	@	60MG	N020625	001	Jul 25, 1996	Jan	CAHN
--	---	------	---------	-----	--------------	-----	------

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

>D>	AB	MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb	DISC
-----	----	-------	---------------	---------	-----	--------------	-----	------

>A>		@	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Feb	DISC
-----	--	---	---------------	---------	-----	--------------	-----	------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

>D>		@ APOTEX INC	50MG	A079164	001	Jul 09, 2009	Feb	CAHN
-----	--	--------------	------	---------	-----	--------------	-----	------

>D>		@	100MG	A079164	002	Jul 09, 2009	Feb	CAHN
-----	--	---	-------	---------	-----	--------------	-----	------

>D>		@	150MG	A079164	003	Jul 09, 2009	Feb	CAHN
-----	--	---	-------	---------	-----	--------------	-----	------

>A>		@ CHARTWELL	50MG	A079164	001	Jul 09, 2009	Feb	CAHN
-----	--	-------------	------	---------	-----	--------------	-----	------

>A>		@	100MG	A079164	002	Jul 09, 2009	Feb	CAHN
-----	--	---	-------	---------	-----	--------------	-----	------

>A>		@	150MG	A079164	003	Jul 09, 2009	Feb	CAHN
-----	--	---	-------	---------	-----	--------------	-----	------

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE

>D>		@ STRIDES PHARMA	250MG	A212632	001	Apr 17, 2020	Feb	CMFD
-----	--	------------------	-------	---------	-----	--------------	-----	------

>A>	AB		250MG	A212632	001	Apr 17, 2020	Feb	CMFD
-----	----	--	-------	---------	-----	--------------	-----	------

>D>		@	500MG	A212632	002	Apr 17, 2020	Feb	CMFD
-----	--	---	-------	---------	-----	--------------	-----	------

>A>	AB		500MG	A212632	002	Apr 17, 2020	Feb	CMFD
-----	----	--	-------	---------	-----	--------------	-----	------

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

>D>	AT	+! ALMIRALL	0.05%	N012806	002		Feb	CTEC
-----	----	-------------	-------	---------	-----	--	-----	------

>A>		+!	0.05%	N012806	002		Feb	CTEC
-----	--	----	-------	---------	-----	--	-----	------

FLURANDRENOLIDE

>D>	AT	CINTEX SVCS	0.05%	A205342	001	Apr 13, 2016	Feb	DISC
-----	----	-------------	-------	---------	-----	--------------	-----	------

>A>		@	0.05%	A205342	001	Apr 13, 2016	Feb	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

LOTION; TOPICAL

FLURANDRENOLIDE

>D>	AT	CINTEX SVCS	0.05%	A205343	001	Dec 22, 2016	Feb	DISC
-----	----	-------------	-------	---------	-----	--------------	-----	------

>A>		@	0.05%	A205343	001	Dec 22, 2016	Feb	DISC
-----	--	---	-------	---------	-----	--------------	-----	------

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

	@ CHARTWELL RX	125MG	A075818	001	Sep 18, 2001	Jan	CAHN
--	----------------	-------	---------	-----	--------------	-----	------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL  
FLUVOXAMINE MALEATE

>D>		@ BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb CMFD
>A>	AB		100MG	A212182	002	Sep 16, 2020	Feb CMFD

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

>D>	AP	PRAXGEN	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Feb DISC
>A>		@	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Feb DISC
>D>	AP		EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Feb DISC
>A>		@	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Feb DISC

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL  
FOSFOMYCIN TROMETHAMINE

AA		CIPLA	EQ 3GM BASE/PACKET	A211881	001	Jan 26, 2022	Jan NEWA
----	--	-------	--------------------	---------	-----	--------------	----------

FULVESTRANT

INJECTABLE;INTRAMUSCULAR  
FULVESTRANT

>A>	AO	@ APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jan DISC
>D>		JIANGSU HANSOH PHARM	50MG/ML	A214682	001	Feb 10, 2022	Feb NEWA
>D>		@ ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Feb CMFD
>A>	AO		50MG/ML	A215234	001	Jul 29, 2021	Feb CMFD

FUROSEMIDE

INJECTABLE;INJECTION  
FUROSEMIDE

AP		HONG KONG	10MG/ML	A212803	001	Jan 27, 2022	Jan NEWA
----	--	-----------	---------	---------	-----	--------------	----------

GABAPENTIN

CAPSULE;ORAL  
NEURONTIN

>D>	AB	+ UPJOHN	100MG	N020235	001	Dec 30, 1993	Feb CAHN
>D>	AB	+	300MG	N020235	002	Dec 30, 1993	Feb CAHN
>D>	AB	+	400MG	N020235	003	Dec 30, 1993	Feb CAHN
>A>	AB	+ VIATRIS	100MG	N020235	001	Dec 30, 1993	Feb CAHN
>A>	AB	+	300MG	N020235	002	Dec 30, 1993	Feb CAHN
>A>	AB	+	400MG	N020235	003	Dec 30, 1993	Feb CAHN

SOLUTION;ORAL  
GABAPENTIN

>D>		@ NOVITIUM PHARMA	250MG/5ML	A211330	001	Dec 03, 2019	Feb CAHN
>A>		@ PAI HOLDINGS PHARM	250MG/5ML	A211330	001	Dec 03, 2019	Feb CAHN
>D>	AA	+	250MG/5ML	N021129	001	Mar 02, 2000	Feb CAHN
>A>	AA	+	250MG/5ML	N021129	001	Mar 02, 2000	Feb CAHN

TABLET;ORAL  
NEURONTIN

>D>	AB	+ UPJOHN	600MG	N020882	001	Oct 09, 1998	Feb CAHN
>D>	AB	+	800MG	N020882	002	Oct 09, 1998	Feb CAHN
>A>	AB	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Feb CAHN
>A>	AB	+	800MG	N020882	002	Oct 09, 1998	Feb CAHN

GANCICLOVIR SODIUM

INJECTABLE;INJECTION  
GANCICLOVIR SODIUM

>D>		@ MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Feb CAHN
>A>		@ STERISCIENCE	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Feb CAHN

GEMFIBROZIL

TABLET;ORAL  
GEMFIBROZIL

>A>		@ CHARTWELL RX	600MG	A074615	001	Sep 29, 1995	Feb CAHN
>D>		@ YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995	Feb CAHN

GEMIFLOXACIN MESYLATE

TABLET;ORAL  
FACTIVE

+ @	LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jan	DISC
	GEMIFLOXACIN MESYLATE						
@	ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jan	DISC

GLIPIZIDE

TABLET;ORAL  
GLIPIZIDE

>A>	AB	AUROBINDO PHARMA USA	5MG	A074226	001	May 10, 1994	Feb	CAHN
>A>	AB		10MG	A074226	002	May 10, 1994	Feb	CAHN
>D>	AB	MYLAN	5MG	A074226	001	May 10, 1994	Feb	CAHN
>D>	AB		10MG	A074226	002	May 10, 1994	Feb	CAHN

GLYBURIDE

TABLET;ORAL  
GLYBURIDE (MICRONIZED)

>A>	@	CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998	Feb	CAHN
>A>	@		3MG	A075174	002	Jun 22, 1998	Feb	CAHN
>D>	@	YAOPHARMA CO LTD	1.5MG	A075174	001	Jun 22, 1998	Feb	CAHN
>D>	@		3MG	A075174	002	Jun 22, 1998	Feb	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION  
GRANISETRON HYDROCHLORIDE

>D>	AP	WOCKHARDT USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078564	001	Jun 30, 2008	Feb	DISC
>A>	@		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078564	001	Jun 30, 2008	Feb	DISC

HYDROCHLOROTHIAZIDE

TABLET;ORAL  
HYDROCHLOROTHIAZIDE

>A>	@	CHARTWELL RX	25MG	A087565	001	Mar 09, 1982	Feb	CAHN
>A>	@		50MG	A084912	001		Feb	CAHN
>D>	@	YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982	Feb	CAHN
>D>	@		50MG	A084912	001		Feb	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL  
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	@	CHARTWELL RX	25MG;40MG	A071060	001	Aug 26, 1987	Feb	CAHN
	@		25MG;80MG	A071061	001	Aug 26, 1987	Jan	CAHN
>D>	@	YAOPHARMA CO LTD	25MG;40MG	A071060	001	Aug 26, 1987	Feb	CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET;ORAL  
MAXZIDE

>A>	AB	+	AUROBINDO PHARMA USA	50MG;75MG	N019129	001	Oct 22, 1984	Feb	CAHN
>D>	AB	+	MYLAN PHARMS INC	50MG;75MG	N019129	001	Oct 22, 1984	Feb	CAHN
			MAXZIDE-25						
>A>	AB	+	AUROBINDO PHARMA USA	25MG;37.5MG	N019129	003	May 13, 1988	Feb	CAHN
>D>	AB	+	MYLAN PHARMS INC	25MG;37.5MG	N019129	003	May 13, 1988	Feb	CAHN
			TRIAMTERENE AND HYDROCHLOROTHIAZIDE						
>A>	AB		RUBICON	25MG;37.5MG	A216211	001	Feb 23, 2022	Feb	NEWA
>A>	AB			50MG;75MG	A216211	002	Feb 23, 2022	Feb	NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL  
HYDROXYCHLOROQUINE SULFATE

!	ACCORD HLTHCARE	400MG	A213342	004	Aug 18, 2021	Jan	CHRS
+	NOVITIUM PHARMA	200MG	N214581	001	Jan 14, 2022	Jan	NEWA
+	!	300MG	N214581	002	Jan 14, 2022	Jan	NEWA

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL  
HYDROXYZINE HYDROCHLORIDE

@	PAI HOLDINGS PHARM	10MG/5ML	A040391	001	Apr 10, 2002	Jan	CAHN
---	--------------------	----------	---------	-----	--------------	-----	------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

>A>	@	CHARTWELL RX	1.25MG	A074594	001	May 23, 1996	Feb	CAHN
>A>	@		2.5MG	A074594	002	May 23, 1996	Feb	CAHN
>D>	@	YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996	Feb	CAHN
>D>	@		2.5MG	A074594	002	May 23, 1996	Feb	CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

+		AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Jan	CTEC
+	!		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Jan	CTEC
			IVABRADINE HYDROCHLORIDE					
	@	CENTAUR PHARMS PVT	EQ 5MG BASE	A214051	001	Dec 30, 2021	Jan	DISC
	@		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	Jan	DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

>D>	@	MYLAN LABS LTD	15MG/ML	A078299	001	Jul 16, 2007	Feb	CAHN
>D>	@		15MG/ML	A201155	001	Aug 04, 2014	Feb	CAHN
>D>	@		30MG/ML	A078299	002	Jul 16, 2007	Feb	CAHN
>D>	@		30MG/ML	A201155	002	Aug 04, 2014	Feb	CAHN
>A>	@	STERISCIENCE	15MG/ML	A078299	001	Jul 16, 2007	Feb	CAHN
>A>	@		15MG/ML	A201155	001	Aug 04, 2014	Feb	CAHN
>A>	@		30MG/ML	A078299	002	Jul 16, 2007	Feb	CAHN
>A>	@		30MG/ML	A201155	002	Aug 04, 2014	Feb	CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

>D>	AT	+	!	OMEROS	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Feb	CAHN
>A>	AT	+	!	RAYNER SURGICAL	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Feb	CAHN

>A> KETOTIFEN FUMARATE

&gt;A&gt; DRUG-ELUTING CONTACT LENS;OPHTHALMIC

&gt;A&gt; ACUVUE THERAVISION WITH KETOTIFEN

>A>	+	!		JOHNSON JOHNSON VISN	EQ 19MCG BASE	N022388	001	Feb 25, 2022	Feb	NEWA
-----	---	---	--	----------------------	---------------	---------	-----	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

>D>	@	MYLAN ASI	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN
>A>	@	STERISCIENCE	5MG/ML	A079134	001	Feb 03, 2010	Feb	CAHN

LAMOTRIGINE

TABLET, FOR SUSPENSION;ORAL

LAMICTAL CD

AB	+			GLAXOSMITHKLINE LLC	2MG	N020764	004	Sep 08, 2000	Jan	CDFR
AB	+				5MG	N020764	001	Aug 24, 1998	Jan	CDFR
AB	+	!			25MG	N020764	002	Aug 24, 1998	Jan	CDFR
			@		100MG	N020764	003	Aug 24, 1998	Jan	CDFR

LAMOTRIGINE

AB				ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	Jan	CDFR
AB					25MG	A201168	002	Jun 12, 2014	Jan	CDFR
AB				AUROBINDO PHARMA	5MG	A090401	002	Nov 04, 2009	Jan	CDFR
AB					25MG	A090401	003	Nov 04, 2009	Jan	CDFR
AB				DR REDDYS LABS LTD	5MG	A076701	001	Jan 22, 2009	Jan	CDFR
AB					25MG	A076701	002	Jan 22, 2009	Jan	CDFR
AB				GLENMARK PHARMS LTD	5MG	A079099	001	Feb 19, 2009	Jan	CDFR
AB					25MG	A079099	002	Feb 19, 2009	Jan	CDFR
			@	JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jan	CDFR
			@		25MG	A200220	002	Feb 28, 2011	Jan	CDFR
			@	MYLAN	5MG	A076630	001	Jan 22, 2009	Jan	CDFR
			@		25MG	A076630	002	Jan 22, 2009	Jan	CDFR
			@	SANDOZ	5MG	A078409	002	Jan 22, 2009	Jan	CDFR
			@		25MG	A078409	003	Jan 22, 2009	Jan	CDFR
AB				TARO	5MG	A079204	001	Feb 04, 2009	Jan	CDFR
AB					25MG	A079204	002	Feb 04, 2009	Jan	CDFR
			@	TEVA	5MG	A076420	001	Jun 21, 2006	Jan	CDFR

TABLET, FOR SUSPENSION;ORAL  
LAMOTRIGINE

	@	25MG	A076420	002	Jun 21, 2006	Jan CDFR
AB	WATSON LABS	2MG	A076928	001	Jan 22, 2009	Jan CDFR
AB		5MG	A076928	002	Jan 22, 2009	Jan CDFR
AB		25MG	A076928	003	Jan 22, 2009	Jan CDFR
AB	ZYDUS PHARMS USA INC	5MG	A078009	002	Jan 22, 2009	Jan CDFR
AB		25MG	A078009	003	Jan 22, 2009	Jan CDFR

TABLET, ORALLY DISINTEGRATING;ORAL  
LAMOTRIGINE

AB	AMRING PHARMS	25MG	A214124	001	Feb 03, 2022	Jan NEWA
AB		50MG	A214124	002	Feb 03, 2022	Jan NEWA
AB		100MG	A214124	003	Feb 03, 2022	Jan NEWA
AB		200MG	A214124	004	Feb 03, 2022	Jan NEWA

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL  
LANTHANUM CARBONATE

AB	BARR	EQ 500MG BASE	A090977	001	Jan 27, 2022	Jan NEWA
AB		EQ 750MG BASE	A090977	002	Jan 27, 2022	Jan NEWA
AB		EQ 1GM BASE	A090977	003	Jan 27, 2022	Jan NEWA
AB	INVAGEN PHARMS	EQ 500MG BASE	A206868	001	Jan 24, 2022	Jan NEWA
AB		EQ 750MG BASE	A206868	002	Jan 24, 2022	Jan NEWA
AB		EQ 1GM BASE	A206868	003	Jan 24, 2022	Jan NEWA

LEFLUNOMIDE

TABLET;ORAL  
LEFLUNOMIDE

AB	AET PHARMA	10MG	A213497	001	May 10, 2021	Jan CMFD
AB		20MG	A213497	002	May 10, 2021	Jan CMFD

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS  
CAMCEVI KIT

+!	ACCORD	EQ 42MG BASE	N211488	001	May 25, 2021	Jan CAHN
----	--------	--------------	---------	-----	--------------	----------

LEVETIRACETAM

TABLET;ORAL  
LEVETIRACETAM

	@	SECAN PHARMS	500MG	A205102	004	Dec 16, 2015	Jan DISC
	@		1GM	A205102	003	Dec 16, 2015	Jan DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL  
XYZAL

+ @	CHATTEM SANOFI	2.5MG/5ML	N022157	001	Jan 28, 2008	Jan CAHN
-----	----------------	-----------	---------	-----	--------------	----------

TABLET;ORAL  
XYZAL

+ @	CHATTEM SANOFI	5MG	N022064	001	May 25, 2007	Jan CAHN
-----	----------------	-----	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

SOLUTION;INTRAVENOUS  
LEVOLEUCOVORIN CALCIUM

>D>	AP	PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Feb DISC
>A>	@		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797	001	Nov 02, 2021	Feb DISC

LEVOTHYROXINE SODIUM

CAPSULE;ORAL  
LEVOTHYROXINE SODIUM

	@	TEVA PHARMS USA INC	0.112MG	A211369	003	Apr 16, 2021	Jan DISC
	+	INSTITUT BIOCHIMIQUE	0.112MG	N021924	008	Oct 02, 2009	Jan CTEC

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL  
LEVOLET

AB1, AB3, AB4	GENUS LIFESCIENCES	0.025MG	N021137	001	Jun 06, 2003	Jan CMFD
---------------------	--------------------	---------	---------	-----	--------------	----------

TABLET;ORAL  
LEVOLET

AB1, AB3, AB4	0.05MG	N021137	002	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.075MG	N021137	003	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.088MG	N021137	004	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.1MG	N021137	005	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.112MG	N021137	006	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.125MG	N021137	007	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.137MG	N021137	008	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.15MG	N021137	009	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.175MG	N021137	010	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.2MG	N021137	011	Jun 06, 2003	Jan CMFD
AB1, AB3, AB4	0.3MG	N021137	012	Jun 06, 2003	Jan CMFD

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE

@ ACRUX DDS PTY	2.5%;2.5%	A212482	001	Jul 27, 2021	Jan DISC
-----------------	-----------	---------	-----	--------------	----------

LISINAPRIL

TABLET;ORAL

LISINAPRIL

@ STRIDES PHARMA	2.5MG	A076071	001	Jul 01, 2002	Jan CAHN
@	5MG	A076071	002	Jul 01, 2002	Jan CAHN
@	10MG	A076071	003	Jul 01, 2002	Jan CAHN
@	20MG	A076071	004	Jul 01, 2002	Jan CAHN
@	30MG	A076071	005	Jul 01, 2002	Jan CAHN
@	40MG	A076071	006	Jul 01, 2002	Jan CAHN

LORAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL

LOREEV XR

>A>	+ ALMATICA	1.5MG	N214826	004	Feb 16, 2022	Feb NEWA
-----	------------	-------	---------	-----	--------------	----------

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

AB	DR REDDYS LABS LTD	8MCG	A206994	001	Feb 08, 2022	Jan NEWA
AB		24MCG	A206994	002	Feb 08, 2022	Jan NEWA
AB	TEVA PHARMS USA INC	8MCG	A209920	001	Jan 18, 2022	Jan NEWA
AB		24MCG	A209920	002	Jan 18, 2022	Jan NEWA

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

>D>	AT	PAR FORM	5%	A201511	001	Feb 12, 2013	Feb CHRS
>A>	AT	!	5%	A201511	001	Feb 12, 2013	Feb CHRS
>D>		SULFAMYLON					
>D>	AT	+! MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Feb DISC
>A>		+ @	5%	N019832	003	Jun 05, 1998	Feb DISC

MARAVIROC

TABLET;ORAL		MARAVIROC					
AB	HETERO LABS LTD III	150MG	A203347	001	Feb 07, 2022	Jan	NFTG
AB		300MG	A203347	002	Feb 07, 2022	Jan	NFTG
SELZENTRY							
AB	+ VIIV HLTHCARE	150MG	N022128	001	Aug 06, 2007	Jan	CFTG
AB	+!	300MG	N022128	002	Aug 06, 2007	Jan	CFTG

MECLIZINE HYDROCHLORIDE

TABLET;ORAL		MECLIZINE HYDROCHLORIDE					
>A>	AA INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Feb	NEWA
>A>	AA	25MG	A200432	002	Feb 17, 2022	Feb	NEWA
>A>	AA	50MG	A200432	003	Feb 17, 2022	Feb	NEWA
TABLET, CHEWABLE;ORAL		MECLIZINE HYDROCHLORIDE					
>A>	AA INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Feb	NEWA

MEMANTINE HYDROCHLORIDE

TABLET;ORAL		MEMANTINE HYDROCHLORIDE					
>A>	AB ALLIED	5MG	A209527	001	May 07, 2018	Feb	CAHN
>A>	AB	10MG	A209527	002	May 07, 2018	Feb	CAHN
>D>	AB CSPC OUYI	5MG	A209527	001	May 07, 2018	Feb	CAHN
>D>	AB	10MG	A209527	002	May 07, 2018	Feb	CAHN
	@ RISING	5MG	A079225	001	Jan 30, 2015	Jan	CAHN
	@	10MG	A079225	002	Jan 30, 2015	Jan	CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL		METFORMIN HYDROCHLORIDE					
>D>	BX AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Feb	CTEC
>A>	AB1	500MG	A078596	001	Jan 03, 2008	Feb	CTEC
>D>	BX	750MG	A078596	002	Jan 03, 2008	Feb	CTEC
>A>	AB	750MG	A078596	002	Jan 03, 2008	Feb	CTEC
	@ AMTA	500MG	A213394	001	Aug 03, 2021	Jan	DISC
	@	1GM	A213394	002	Aug 03, 2021	Jan	DISC
>A>	AB2 SCIEGEN PHARMS INC	500MG	A214629	001	Feb 22, 2022	Feb	NEWA
>A>	AB2	1GM	A214629	002	Feb 22, 2022	Feb	NEWA

METHADONE HYDROCHLORIDE

TABLET;ORAL		METHADONE HYDROCHLORIDE					
>D>	AA NOSTRUM LABS INC	5MG	A210484	001	Aug 02, 2018	Feb	DISC
>A>	@	5MG	A210484	001	Aug 02, 2018	Feb	DISC
>D>	AA	10MG	A210484	002	Aug 02, 2018	Feb	DISC
>A>	@	10MG	A210484	002	Aug 02, 2018	Feb	DISC

METHOTREXATE SODIUM

INJECTABLE;INJECTION		METHOTREXATE LPF					
	+ @ HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982	Jan	CRLD
METHOTREXATE PRESERVATIVE FREE							
	+ @ HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005	Jan	CRLD
	+ @	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005	Jan	CRLD
METHOTREXATE SODIUM							
	+ @ HOSPIRA	EQ 2.5MG BASE/ML	N011719	004		Jan	CRLD
	+ @	EQ 20MG BASE/VIAL	N011719	001		Jan	CRLD
	+ @	EQ 25MG BASE/ML	N011719	005		Jan	CRLD
	+ @	EQ 50MG BASE/VIAL	N011719	003		Jan	CRLD
	+ @	EQ 100MG BASE/VIAL	N011719	006		Jan	CRLD
METHOTREXATE SODIUM PRESERVATIVE FREE							
AP	HIKMA	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Jan	CHRS
	+ @ HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988	Jan	CRLD
MEXATE-AQ							
	+ @ BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985	Jan	CRLD

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ACTAVIS LABS FL	72MG	A076655	002	Feb 28, 2022	Feb NEWA
>D>	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Feb CTEC
>A>	AB	!	72MG	A205327	005	Jul 28, 2017	Feb CTEC

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION  
METHYLPREDNISOLONE ACETATE

AB	PAR STERILE PRODUCTS	40MG/ML	A214297	001	Jan 21, 2022	Jan NEWA
AB		80MG/ML	A214297	002	Jan 21, 2022	Jan NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION  
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Jan CMFD
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Jan CMFD
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Jan CMFD
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Jan CMFD
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Jan CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL  
METHYLTESTOSTERONE

>D>	!	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Feb CTEC
>A>	AB	!	10MG	A204851	001	Sep 21, 2015	Feb CTEC
>A>	AB	NOVITIUM PHARMA	10MG	A215270	001	Feb 18, 2022	Feb NEWA

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION  
REGLAN

+	@	HIKMA	EQ 5MG BASE/ML	N017862	001		Jan CRLD
---	---	-------	----------------	---------	-----	--	----------

METOPROLOL TARTRATE

INJECTABLE;INJECTION  
METOPROLOL TARTRATE

>D>	@	MYLAN ASI	1MG/ML	A090317	001	Apr 19, 2010	Feb CAHN
>A>	@	STERISCIENCE	1MG/ML	A090317	001	Apr 19, 2010	Feb CAHN

METRONIDAZOLE

GEL;VAGINAL  
METRONIDAZOLE

AB	GLENMARK PHARMS LTD	0.75%	A215794	001	Jan 27, 2022	Jan NEWA
----	---------------------	-------	---------	-----	--------------	----------

INJECTABLE;INJECTION  
METRONIDAZOLE IN PLASTIC CONTAINER  
@ RISING 500MG/100ML

A205531	001	May 09, 2017	Jan CAHN
---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION  
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

@	STERISCIENCE	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010	Jan CAHN
@		EQ 5MG BASE/ML	A090315	002	Nov 29, 2010	Jan CAHN

MIDOZALAM HYDROCHLORIDE

>D>	@	MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Feb CAHN
>D>	@		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Feb CAHN
>A>	@	STERISCIENCE	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Feb CAHN
>A>	@		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Feb CAHN

MIGLUSTAT

CAPSULE;ORAL  
MIGLUSTAT

AB	BRECKENRIDGE	100MG	A209325	001	Feb 03, 2022	Jan NEWA
----	--------------	-------	---------	-----	--------------	----------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL  
AMZEEQ

+	!	JOURNEY	EQ 4% BASE	N212379	001	Oct 18, 2019	Jan CAHN
---	---	---------	------------	---------	-----	--------------	----------

ZILXI

+	!	JOURNEY	EQ 1.5% BASE	N213690	001	May 28, 2020	Jan CAHN
---	---	---------	--------------	---------	-----	--------------	----------



MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL  
MIRTAZAPINE

AB	SQUARE PHARMS	15MG	A205798	001	Jun 01, 2017	Jan CAHN
AB		30MG	A205798	002	Jun 01, 2017	Jan CAHN
AB		45MG	A205798	003	Jun 01, 2017	Jan CAHN

>A> MITAPIVAT SULFATE

>A> TABLET;ORAL  
>A> PYRUKYND

>A>	+	AGIOS PHARMS INC	EQ 5MG BASE	N216196	001	Feb 17, 2022	Feb NEWA
>A>	+		EQ 20MG BASE	N216196	002	Feb 17, 2022	Feb NEWA
>A>	+	!	EQ 50MG BASE	N216196	003	Feb 17, 2022	Feb NEWA

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL  
RYALTRIS

+	!	GLENMARK SPECIALTY	0.025MG/SPRAY;0.665MG/SPRAY	N211746	001	Jan 13, 2022	Jan NEWA
---	---	--------------------	-----------------------------	---------	-----	--------------	----------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL  
MORPHINE SULFATE

@	NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jan DISC
@		30MG	A203158	002	Aug 04, 2021	Jan DISC
@		50MG	A203158	003	Aug 04, 2021	Jan DISC
@		60MG	A203158	004	Aug 04, 2021	Jan DISC
@		80MG	A203158	005	Aug 04, 2021	Jan DISC
@		100MG	A203158	006	Aug 04, 2021	Jan DISC

INJECTABLE;INJECTION  
MORPHINE SULFATE

+	@	HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021	Jan DISC
		INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021	Jan CMFD

TABLET;ORAL  
MORPHINE SULFATE

>D>	AB	RICONPHARMA LLC	15MG	A215584	001	Feb 07, 2022	Feb DISC
>A>		@	15MG	A215584	001	Feb 07, 2022	Feb DISC
	AB		15MG	A215584	001	Feb 07, 2022	Jan NEWA
>D>	AB		30MG	A215584	002	Feb 07, 2022	Feb DISC
>A>		@	30MG	A215584	002	Feb 07, 2022	Feb DISC
	AB		30MG	A215584	002	Feb 07, 2022	Jan NEWA

MYCOPHENOLATE MOFETIL

FOR SUSPENSION;ORAL  
MYCOPHENOLATE MOFETIL

AB	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Jan NEWA
----	-----------------	----------	---------	-----	--------------	----------

NAFCILLIN SODIUM

INJECTABLE;INJECTION  
NAFCILLIN SODIUM

>D>		@	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Feb CAHN
>D>		@		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Feb CAHN
>A>		@	STERISCIENCE	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Feb CAHN
>A>		@		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Feb CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION  
REVEX

+	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CPOT
+	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CPOT
SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
NALMEFENE HYDROCHLORIDE							
!		PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	Jan NEWA
REVEX							
+	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N020459	001	Apr 17, 1995	Jan CDFR
+	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	N020459	002	Apr 17, 1995	Jan CDFR

NALOXONE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

>A> NALOXONE HYDROCHLORIDE (AUTOINJECTOR)  
 >A> +! KALEO INC 10MG/0.4ML (10MG/0.4ML) N215457 001 Feb 28, 2022 Feb NEWA

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

>A> AB MACLEODS PHARMS LTD 500MG A204934 001 Mar 03, 2022 Feb NEWA  
 >A> AB 1GM A204934 002 Mar 03, 2022 Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>A> AB INVENTIA 75MG;25MG A211013 001 Feb 18, 2022 Feb NEWA

NITROGLYCERIN

TABLET;SUBLINGUAL

NITROGLYCERIN

>A> AB ZYDUS PHARMS 0.3MG A210153 001 Mar 08, 2022 Feb NEWA  
 >A> AB 0.4MG A210153 002 Mar 08, 2022 Feb NEWA  
 >A> AB 0.6MG A210153 003 Mar 08, 2022 Feb NEWA  
 NITROSTAT  
 AB + VIATRIS 0.3MG N021134 001 May 01, 2000 Jan CAHN  
 AB + 0.4MG N021134 002 May 01, 2000 Jan CAHN  
 AB +! 0.6MG N021134 003 May 01, 2000 Jan CAHN

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

>A> @ AUROBINDO PHARMA LTD EQ 10MG BASE A074835 001 Jun 30, 1997 Feb CAHN  
 >A> @ EQ 25MG BASE A074835 002 Jun 30, 1997 Feb CAHN  
 >A> @ EQ 50MG BASE A074835 003 Jun 30, 1997 Feb CAHN  
 >A> @ EQ 75MG BASE A074835 004 Jun 30, 1997 Feb CAHN  
 >D> @ AUROLIFE PHARMA LLC EQ 10MG BASE A074835 001 Jun 30, 1997 Feb CAHN  
 >D> @ EQ 25MG BASE A074835 002 Jun 30, 1997 Feb CAHN  
 >D> @ EQ 50MG BASE A074835 003 Jun 30, 1997 Feb CAHN  
 >D> @ EQ 75MG BASE A074835 004 Jun 30, 1997 Feb CAHN

NYSTATIN

SUSPENSION;ORAL

NYSTATIN

>A> AA MEDLEY PHARMS 100,000 UNITS/ML A214346 001 Mar 10, 2022 Feb NEWA

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

>A> AT ALEOR DERMACEUTICALS 100,000 UNITS/GM;0.1% A214186 001 Mar 04, 2022 Feb NEWA

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE;ORAL

MYCAPSSA

+! AMRYT EQ 20MG BASE N208232 001 Jun 26, 2020 Jan CAHN

OFLOXACIN

SOLUTION/DROPS;OTIC

OFLOXACIN

AT FDC LTD 0.3% A215038 001 Jan 19, 2022 Jan NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

@ STRIDES PHARMA 10MG A075876 001 May 29, 2003 Jan CAHN  
 @ 20MG A075876 002 May 29, 2003 Jan CAHN  
 @ 40MG A075876 003 Jan 21, 2009 Jan CAHN

ONDANSETRON HYDROCHLORIDE

## INJECTABLE; INJECTION

## ONDANSETRON HYDROCHLORIDE

>D>	@ MYLAN LABS LTD	EQ 2MG BASE/ML	A 078257	001	Apr 23, 2008	Feb	CAHN
>A>	@ STERISCIENCE	EQ 2MG BASE/ML	A 078257	001	Apr 23, 2008	Feb	CAHN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
>D>	@ MYLAN LABS LTD	EQ 2MG BASE/ML	A 078244	001	Apr 23, 2008	Feb	CAHN
>A>	@ STERISCIENCE	EQ 2MG BASE/ML	A 078244	001	Apr 23, 2008	Feb	CAHN

## TABLET; ORAL

## ONDANSETRON HYDROCHLORIDE

>D>	AB	AUROBINDO PHARMA	EQ 24MG BASE	A 078539	003	Jul 31, 2007	Feb	DISC
>A>		@	EQ 24MG BASE	A 078539	003	Jul 31, 2007	Feb	DISC
>D>	AB	CASI PHARMS INC	EQ 24MG BASE	A 077517	003	Jun 25, 2007	Feb	DISC
>A>		@	EQ 24MG BASE	A 077517	003	Jun 25, 2007	Feb	DISC
>D>	AB	DR REDDYS LABS LTD	EQ 24MG BASE	A 076183	001	Dec 26, 2006	Feb	DISC
>A>		@	EQ 24MG BASE	A 076183	001	Dec 26, 2006	Feb	DISC
>D>	AB	GLENMARK GENERICS	EQ 8MG BASE	A 077535	002	Jun 25, 2007	Feb	CHRS
>A>	AB	!	EQ 8MG BASE	A 077535	002	Jun 25, 2007	Feb	CHRS
>D>	AB		EQ 24MG BASE	A 077535	003	Jun 25, 2007	Feb	DISC
>A>		@	EQ 24MG BASE	A 077535	003	Jun 25, 2007	Feb	DISC
>D>	AB	TEVA	EQ 4MG BASE	A 076252	001	Jun 25, 2007	Feb	DISC
>A>		@	EQ 4MG BASE	A 076252	001	Jun 25, 2007	Feb	DISC
>D>	AB		EQ 8MG BASE	A 076252	002	Jun 25, 2007	Feb	DISC
>A>		@	EQ 8MG BASE	A 076252	002	Jun 25, 2007	Feb	DISC
>D>	AB		EQ 24MG BASE	A 076252	003	Jun 25, 2007	Feb	DISC
>A>		@	EQ 24MG BASE	A 076252	003	Jun 25, 2007	Feb	DISC
ZOFTRAN								
>D>	AB	+ NOVARTIS	EQ 4MG BASE	N 020103	001	Dec 31, 1992	Feb	DISC
>A>		+ @	EQ 4MG BASE	N 020103	001	Dec 31, 1992	Feb	DISC
>D>	AB	+	EQ 8MG BASE	N 020103	002	Dec 31, 1992	Feb	DISC
>A>		+ @	EQ 8MG BASE	N 020103	002	Dec 31, 1992	Feb	DISC
>D>	AB	+!	EQ 24MG BASE	N 020103	003	Aug 27, 1999	Feb	DISC
>A>		+ @	EQ 24MG BASE	N 020103	003	Aug 27, 1999	Feb	DISC

OSELTAMIVIR PHOSPHATE

## FOR SUSPENSION; ORAL

## OSELTAMIVIR PHOSPHATE

>A>	AB	LEADING PHARMA LLC	EQ 6MG BASE/ML	A 214949	001	Feb 28, 2022	Feb	NEWA
	AB	STRIDES PHARMA	EQ 6MG BASE/ML	A 211894	001	Jan 13, 2022	Jan	NEWA

OXACILLIN SODIUM

## INJECTABLE; INJECTION

## OXACILLIN SODIUM

>D>		@ MYLAN LABS LTD	EQ 1GM BASE/VIAL	A 091486	001	Aug 25, 2014	Feb	CAHN
>D>		@	EQ 2GM BASE/VIAL	A 091486	002	Aug 25, 2014	Feb	CAHN
>A>		@ STERISCIENCE	EQ 1GM BASE/VIAL	A 091486	001	Aug 25, 2014	Feb	CAHN
>A>		@	EQ 2GM BASE/VIAL	A 091486	002	Aug 25, 2014	Feb	CAHN

OXAZEPAM

## CAPSULE; ORAL

## SERAX

		+ @ ALPHARMA US PHARMS	10MG	N 015539	002		Jan	CRLD
		+ @	15MG	N 015539	004		Jan	CRLD
		+ @	30MG	N 015539	006		Jan	CRLD

OXYCODONE HYDROCHLORIDE

## SOLUTION; ORAL

## OXYCODONE HYDROCHLORIDE

>D>	AA	NOVEL LABS INC	100MG/5ML	A 204603	001	Apr 29, 2015	Feb	DISC
>A>		@	100MG/5ML	A 204603	001	Apr 29, 2015	Feb	DISC

## TABLET; ORAL

## ROXYBOND

>D>		@ OHEMO LIFE	5MG	N 209777	001	Apr 20, 2017	Feb	CAHN
>D>		@	15MG	N 209777	002	Apr 20, 2017	Feb	CAHN
>D>		@	30MG	N 209777	003	Apr 20, 2017	Feb	CAHN
>A>		@ PROTEGA PHARMS	5MG	N 209777	001	Apr 20, 2017	Feb	CAHN
>A>		@	15MG	N 209777	002	Apr 20, 2017	Feb	CAHN
>A>		@	30MG	N 209777	003	Apr 20, 2017	Feb	CAHN

PACLITAXEL

INJECTABLE; INJECTION

>D>		PACTAXEL							
>D>	AP	GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Feb	CTNA	
>A>		PACLITAXEL							
>A>	AP	GLAND PHARMA LTD	6MG/ML	A207326	001	Aug 23, 2016	Feb	CTNA	

PACRITINIB CITRATE

CAPSULE; ORAL

VONJO

>A>	+	CTI BIOPHARMA CORP	EQ 100MG BASE	N208712	001	Feb 28, 2022	Feb	NEWA	
-----	---	--------------------	---------------	---------	-----	--------------	-----	------	--

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

@	EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jan	DISC	
---	-------------------	---	---------	-----	--------------	-----	------	--

@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jan	DISC	
---	--	--	---------	-----	--------------	-----	------	--

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

>A>	+	@ APOTEX	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb	CAHN	
>A>	+	@	EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb	CAHN	
>A>	+	@	EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb	CAHN	
>A>	+	@	EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb	CAHN	
>D>	+	@ APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb	CAHN	
>D>	+	@	EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb	CAHN	
>D>	+	@	EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb	CAHN	
>D>	+	@	EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb	CAHN	

SUSPENSION; ORAL

PAXIL

>A>	AB	+	APOTEX	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb	CAHN
>D>	AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb	CAHN

TABLET; ORAL

PAXIL

>A>	AB	+	APOTEX	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb	CAHN
>A>	AB	+		EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb	CAHN
>A>	AB	+		EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb	CAHN
>A>	AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb	CAHN
>A>		@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb	CAHN
>D>	AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Feb	CAHN
>D>	AB	+		EQ 20MG BASE	N020031	002	Dec 29, 1992	Feb	CAHN
>D>	AB	+		EQ 30MG BASE	N020031	003	Dec 29, 1992	Feb	CAHN
>D>	AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Feb	CAHN
>D>		@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

@	SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jan	DISC	
---	----------------------	----------------	---------	-----	--------------	-----	------	--

@		EQ 25MG BASE	A213612	002	Aug 11, 2021	Jan	DISC	
---	--	--------------	---------	-----	--------------	-----	------	--

PAXIL CR

>A>	AB	+	APOTEX	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb	CAHN
>A>	AB	+		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb	CAHN
>A>	AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb	CAHN
>D>	AB	+	APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb	CAHN
>D>	AB	+		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb	CAHN
>D>	AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

>D>	AA	!	SANDOZ	30MG	A087190	001		Feb	CRLD
>A>	AA	+		30MG	A087190	001		Feb	CRLD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>D>		@	ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Feb	CMFD
>A>	AP1			10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020	Feb	CMFD
>D>		@		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Feb	CMFD

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>A>	AP1		50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020	Feb	CMFD
>D>	@		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Feb	CMFD
>A>	AP1		100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020	Feb	CMFD
	@	PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Jan	DISC

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-125

>D>	AB	+	UPJOHN	125MG/5ML	N008762	001		Feb	CAHN
>A>	AB	+	VIATRIS	125MG/5ML	N008762	001		Feb	CAHN
			DILANTIN-30						
>D>	@		UPJOHN	30MG/5ML	N008762	002		Feb	CAHN
>A>	@		VIATRIS	30MG/5ML	N008762	002		Feb	CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

DILANTIN

>D>		+	UPJOHN	30MG EXTENDED	A084349	001		Feb	CAHN
>D>	AB	+		100MG EXTENDED	A084349	002		Feb	CAHN
>A>		+	VIATRIS	30MG EXTENDED	A084349	001		Feb	CAHN
>A>	AB	+		100MG EXTENDED	A084349	002		Feb	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	@	MYLAN LABS LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Feb	CAHN
>D>	@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Feb	CAHN
>D>	@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Feb	CAHN
>A>	@	STERISCIENCE	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Feb	CAHN
>A>	@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Feb	CAHN
>A>	@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Feb	CAHN

PIRFENIDONE

CAPSULE;ORAL

PIRFENIDONE

AB		ACCORD HLTHCARE	267MG	A212731	001	Jan 20, 2022	Jan	NEWA
	@	AMNEAL	267MG	A212569	001	Jan 03, 2022	Jan	DISC

TABLET;ORAL

ESBRIET

AB	+	GENENTECH INC	267MG	N208780	001	Jan 11, 2017	Jan	CFTG
AB	+		801MG	N208780	003	Jan 11, 2017	Jan	CFTG

PIRFENIDONE

AB		ACCORD HLTHCARE	267MG	A212730	001	Jan 25, 2022	Jan	NFTG
AB			801MG	A212730	002	Jan 25, 2022	Jan	NFTG
AB		TEVA PHARMS USA	267MG	A212759	001	Jan 25, 2022	Jan	NFTG
AB			801MG	A212759	002	Jan 25, 2022	Jan	NFTG

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

>D>	AA		NOVEL LABS INC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090019	001	May 27, 2009	Feb	DISC
>A>	@			420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT	A090019	001	May 27, 2009	Feb	DISC

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

>D>	AB		MYLAN	1MG	A210275	001	Jan 26, 2022	Feb	CAHN
>A>	@			1MG	A210275	001	Jan 26, 2022	Feb	CAHN
	AB			1MG	A210275	001	Jan 26, 2022	Jan	NEWA
>D>	AB			2MG	A210275	002	Jan 26, 2022	Feb	CAHN
>A>	@			2MG	A210275	002	Jan 26, 2022	Feb	CAHN
	AB			2MG	A210275	002	Jan 26, 2022	Jan	NEWA
>D>	AB			3MG	A210275	003	Jan 26, 2022	Feb	CAHN
>A>	@			3MG	A210275	003	Jan 26, 2022	Feb	CAHN

		CAPSULE;ORAL							
		POMALIDOMIDE							
	AB		3MG	A210275	003	Jan 26, 2022	Jan	NEWA	
>D>	AB		4MG	A210275	004	Jan 26, 2022	Feb	CAHN	
>A>		@	4MG	A210275	004	Jan 26, 2022	Feb	CAHN	
	AB		4MG	A210275	004	Jan 26, 2022	Jan	NEWA	
		POMALYST							
>D>	AB	+	CELGENE	1MG	N204026	001	Feb 08, 2013	Feb	CTEC
>A>		+		1MG	N204026	001	Feb 08, 2013	Feb	CTEC
	AB	+		1MG	N204026	001	Feb 08, 2013	Jan	CTEC
>D>	AB	+		2MG	N204026	002	Feb 08, 2013	Feb	CTEC
>A>		+		2MG	N204026	002	Feb 08, 2013	Feb	CTEC
	AB	+		2MG	N204026	002	Feb 08, 2013	Jan	CTEC
>D>	AB	+		3MG	N204026	003	Feb 08, 2013	Feb	CTEC
>A>		+		3MG	N204026	003	Feb 08, 2013	Feb	CTEC
	AB	+		3MG	N204026	003	Feb 08, 2013	Jan	CTEC
>D>	AB	+		4MG	N204026	004	Feb 08, 2013	Feb	CTEC
>A>		+		4MG	N204026	004	Feb 08, 2013	Feb	CTEC
	AB	+		4MG	N204026	004	Feb 08, 2013	Jan	CTEC
		<u>POSACONAZOLE</u>							
		FOR SUSPENSION, DELAYED RELEASE;ORAL							
		NOXAFIL POWDERMIX KIT							
		+	@ MSD MERCK CO	300MG	N214770	001	May 31, 2021	Jan	DISC
		TABLET, DELAYED RELEASE;ORAL							
		POSACONAZOLE							
	AB		BIOCON PHARMA	100MG	A214476	001	Feb 04, 2022	Jan	NEWA
		<u>POTASSIUM CHLORIDE</u>							
		FOR SOLUTION;ORAL							
		POTASSIUM CHLORIDE							
	AA		GRANULES	20MEQ	A213467	001	Jan 27, 2022	Jan	NEWA
		SOLUTION;ORAL							
		POTASSIUM CHLORIDE							
	AA		RUBICON	20MEQ/15ML	A214656	001	Jan 13, 2022	Jan	NEWA
	AA			40MEQ/15ML	A214656	002	Jan 13, 2022	Jan	NEWA
	AA		TRIS PHARMA INC	20MEQ/15ML	A214076	001	Jan 26, 2022	Jan	NEWA
	AA			40MEQ/15ML	A214076	002	Jan 26, 2022	Jan	NEWA
		<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>							
		TABLET, EXTENDED RELEASE;ORAL							
		PRAMIPEXOLE DIHYDROCHLORIDE							
	AB		NOVAST LABS	0.375MG	A213444	001	Feb 03, 2022	Jan	NEWA
	AB			0.75MG	A213444	002	Feb 03, 2022	Jan	NEWA
	AB			1.5MG	A213444	003	Feb 03, 2022	Jan	NEWA
	AB			2.25MG	A213444	004	Feb 03, 2022	Jan	NEWA
	AB			3MG	A213444	005	Feb 03, 2022	Jan	NEWA
	AB			3.75MG	A213444	006	Feb 03, 2022	Jan	NEWA
	AB			4.5MG	A213444	007	Feb 03, 2022	Jan	NEWA
		<u>PRAZOSIN HYDROCHLORIDE</u>							
		CAPSULE;ORAL							
		PRAZOSIN HYDROCHLORIDE							
>D>	AB		ANI PHARMS	EQ 5MG BASE	A072577	003	May 16, 1989	Feb	DISC
>A>		@		EQ 5MG BASE	A072577	003	May 16, 1989	Feb	DISC
		<u>PREGABALIN</u>							
		CAPSULE;ORAL							
		PREGABALIN							
>A>	AB		ALLIED	50MG	A210585	001	Dec 26, 2019	Feb	CAHN
>A>	AB			75MG	A210585	002	Dec 26, 2019	Feb	CAHN
>A>	AB			100MG	A210585	003	Dec 26, 2019	Feb	CAHN
>A>	AB			150MG	A210585	004	Dec 26, 2019	Feb	CAHN
>A>	AB			200MG	A210585	005	Dec 26, 2019	Feb	CAHN
>A>	AB			300MG	A210585	006	Dec 26, 2019	Feb	CAHN
>D>	AB		CSPC OUYI	50MG	A210585	001	Dec 26, 2019	Feb	CAHN
>D>	AB			75MG	A210585	002	Dec 26, 2019	Feb	CAHN
>D>	AB			100MG	A210585	003	Dec 26, 2019	Feb	CAHN
>D>	AB			150MG	A210585	004	Dec 26, 2019	Feb	CAHN
>D>	AB			200MG	A210585	005	Dec 26, 2019	Feb	CAHN
>D>	AB			300MG	A210585	006	Dec 26, 2019	Feb	CAHN
>A>	AB		ESKAYEF	25MG	A212988	001	Mar 08, 2022	Feb	NEWA

CAPSULE;ORAL  
PREGABALIN

>A>	AB		50MG	A212988	002	Mar 08, 2022	Feb	NEWA
>A>	AB		75MG	A212988	003	Mar 08, 2022	Feb	NEWA
>A>	AB		100MG	A212988	004	Mar 08, 2022	Feb	NEWA
>A>	AB		150MG	A212988	005	Mar 08, 2022	Feb	NEWA
>A>	AB		200MG	A212988	006	Mar 08, 2022	Feb	NEWA
>A>	AB		225MG	A212988	007	Mar 08, 2022	Feb	NEWA
>A>	AB		300MG	A212988	008	Mar 08, 2022	Feb	NEWA

SOLUTION;ORAL  
PREGABALIN

>A>	AA	INVATECH	20MG/ML	A212604	001	Feb 18, 2022	Feb	NEWA
-----	----	----------	---------	---------	-----	--------------	-----	------

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION  
PROPRANOLOL HYDROCHLORIDE

>D>	AP	ATHENEX INC	1MG/ML	A075792	001	Aug 29, 2000	Feb	DISC
>A>		@	1MG/ML	A075792	001	Aug 29, 2000	Feb	DISC
>D>		! HIKMA FARMACEUTICA	1MG/ML	A077760	001	Jan 31, 2008	Feb	CTEC
>A>	AP	!	1MG/ML	A077760	001	Jan 31, 2008	Feb	CTEC

RANOLAZINE

>A>		GRANULES, EXTENDED RELEASE;ORAL						
>A>		ASPRUZYO SPRINKLE						
>A>		+ SUN PHARMA GLOBAL	500MG	N216018	001	Feb 28, 2022	Feb	NEWA
>A>		+!	1GM	N216018	002	Feb 28, 2022	Feb	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		RANOLAZINE						
AB		VKT PHARMA	500MG	A214035	001	Jan 19, 2022	Jan	NEWA
AB			1GM	A214035	002	Jan 19, 2022	Jan	NEWA

RASAGILINE MESYLATE

TABLET;ORAL  
RASAGILINE MESYLATE

@	DR REDDYS	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Jan	DISC
@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Jan	DISC

RILUZOLE

SUSPENSION;ORAL  
TIGLUTIK KIT

+!	ITALFARMACO SPA	50MG/10ML	N209080	001	Sep 05, 2018	Jan	CAHN
----	-----------------	-----------	---------	-----	--------------	-----	------

ROFLUMILAST

TABLET;ORAL  
ROFLUMILAST

>A>	AB	ZYDUS PHARMS	500MCG	A208303	001	Feb 10, 2022	Feb	NEWA
-----	----	--------------	--------	---------	-----	--------------	-----	------

ROSUVASTATIN CALCIUM

TABLET;ORAL  
ROSUVASTATIN CALCIUM

@	STRIDES PHARMA	EQ 5MG BASE	A079161	001	Jul 19, 2016	Jan	CAHN
@		EQ 10MG BASE	A079161	002	Jul 19, 2016	Jan	CAHN
@		EQ 20MG BASE	A079161	003	Jul 19, 2016	Jan	CAHN
@		EQ 40MG BASE	A079161	004	Jul 19, 2016	Jan	CAHN

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION  
QUADRAMET

+ @	LANTHEUS MEDICAL	50mCi/ML	N020570	001	Mar 28, 1997	Jan	DISC
-----	------------------	----------	---------	-----	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE;ORAL  
ZOLOFT

AA	+!	VIATRIS	EQ 20MG BASE/ML	N020990	001	Dec 07, 1999	Jan	CAHN
----	----	---------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL  
ZOLOFT

AB	+	VIATRIS	EQ 25MG BASE	N019839	005	Mar 06, 1996	Jan	CAHN
AB	+		EQ 50MG BASE	N019839	001	Dec 30, 1991	Jan	CAHN
AB	+!		EQ 100MG BASE	N019839	002	Dec 30, 1991	Jan	CAHN
	+	@	EQ 150MG BASE	N019839	003	Dec 30, 1991	Jan	CAHN
	+	@	EQ 200MG BASE	N019839	004	Dec 30, 1991	Jan	CAHN

SEVELAMER CARBONATE

TABLET;ORAL

AB	SEVELAMER CARBONATE	800MG	A215537	001	Feb 07, 2022	Jan NEWA
	MICRO LABS					
	@ STRIDES PHARMA	800MG	A201069	001	Aug 05, 2020	Jan CAHN

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

>D>	AB	+!	UPJOHN	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Feb CAHN
>A>	AB	+!	VIATRIS	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	Feb CAHN

SILDENAFIL CITRATE

AB	MSN	EQ 10MG BASE/ML	A214641	001	Feb 08, 2022	Jan NEWA
----	-----	-----------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS

REVATIO

>D>	AP	+!	UPJOHN	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Feb CAHN
>A>	AP	+!	VIATRIS	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Feb CAHN

TABLET;ORAL

REVATIO

>D>	AB	+!	UPJOHN	EQ 20MG BASE	N021845	001	Jun 03, 2005	Feb CAHN
>A>	AB	+!	VIATRIS	EQ 20MG BASE	N021845	001	Jun 03, 2005	Feb CAHN

VIAGRA

>D>	AB	+	UPJOHN	EQ 25MG BASE	N020895	001	Mar 27, 1998	Feb CAHN
>D>	AB	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	Feb CAHN
>D>	AB	+!		EQ 100MG BASE	N020895	003	Mar 27, 1998	Feb CAHN
>A>	AB	+	VIATRIS	EQ 25MG BASE	N020895	001	Mar 27, 1998	Feb CAHN
>A>	AB	+		EQ 50MG BASE	N020895	002	Mar 27, 1998	Feb CAHN
>A>	AB	+!		EQ 100MG BASE	N020895	003	Mar 27, 1998	Feb CAHN

SILODOSIN

CAPSULE;ORAL

SILODOSIN

>D>	AB		UPSHER SMITH LABS	4MG	A213230	001	Jan 03, 2022	Feb DISC
>A>			@	4MG	A213230	001	Jan 03, 2022	Feb DISC
>D>	AB			8MG	A213230	002	Jan 03, 2022	Feb DISC
>A>			@	8MG	A213230	002	Jan 03, 2022	Feb DISC

SODIUM CHLORIDE

SOLUTION;INTRAVENOUS

SODIUM CHLORIDE 23.4%

>A>	AP		FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A212070	003	Feb 14, 2022	Feb NFTG
>D>		+!	HOSPIRA	400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Feb CFTG
>A>	AP	+!		400MEQ/100ML (4MEQ/ML)	N018897	003	Jun 18, 2020	Feb CFTG

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

SODIUM NITROPRUSSIDE

@ BE PHARMS

25MG/ML

A214971 001 Jul 12, 2021 Jan DISC

SOFOBUVIR

TABLET;ORAL

SOFOBUVIR

AB	TEVA PHARMS USA INC	400MG	A211353	001	Jan 27, 2022	Jan NFTG	
	SOVALDI						
AB	+!	GILEAD SCIENCES INC	400MG	N204671	001	Dec 06, 2013	Jan CFTG

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

@ AMNEAL PHARMS CO

5MG

A209719 001 May 20, 2019 Jan DISC

@

10MG

A209719 002 May 20, 2019 Jan DISC

SONIDEGIB PHOSPHATE

CAPSULE;ORAL

ODOMZO

>A>		+!	SUN PHARM	EQ 200MG BASE	N205266	001	Jul 24, 2015	Feb CAHN
>D>		+!	SUN PHARMA GLOBAL	EQ 200MG BASE	N205266	001	Jul 24, 2015	Feb CAHN



STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

>D>	!	MEDEFIL INC	100% (5ML)	A211188	004	Dec 02, 2019	Feb CTEC
>A>	AP	!	100% (5ML)	A211188	004	Dec 02, 2019	Feb CTEC
>D>	@	NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Feb CMFD
>A>	AP		100% (5ML)	A211222	001	Feb 10, 2021	Feb CMFD

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

SUCCINYLCHOLINE CHLORIDE

AP		BE PHARMS	20MG/ML	A216003	001	Feb 07, 2022	Jan NEWA
----	--	-----------	---------	---------	-----	--------------	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		NOVITIUM PHARMA	200MG/5ML; 40MG/5ML	A214330	001	Feb 08, 2022	Jan NEWA
----	--	-----------------	---------------------	---------	-----	--------------	----------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

>D>	@	MYLAN ASI	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb CAHN
>D>	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb CAHN
>A>	@	STERISCIENCE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090314	001	Jun 10, 2010	Feb CAHN
>A>	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090641	001	Jul 28, 2010	Feb CAHN

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

TAFLUPROST

AT		SANDOZ INC	0.0015%	A209040	001	Jan 28, 2022	Jan NEWA
----	--	------------	---------	---------	-----	--------------	----------

>A>		<u>TECHNETIUM TC-99M SUCCIMER KIT</u>						
>A>		POWDER; INTRAVENOUS						
>A>		NEPHROSCAN						
>A>	+	!	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022	Feb NEWA

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVIEW

>D>	+	@	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996	Feb CMFD
>A>	+	!		N/A	N020372	001	Feb 09, 1996	Feb CMFD

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB		HERITAGE	5MG	A078879	001	Mar 01, 2010	Jan CMFD
AB			20MG	A078879	002	Mar 01, 2010	Jan CMFD
AB			100MG	A078879	003	Mar 01, 2010	Jan CMFD
AB			140MG	A078879	005	Mar 01, 2010	Jan CMFD
AB			180MG	A078879	006	Mar 01, 2010	Jan CMFD
AB			250MG	A078879	004	Mar 01, 2010	Jan CMFD

TENAPANOR HYDROCHLORIDE

TABLET; ORAL

IBSRELA

>D>	+	@	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Feb CMFD
>A>	+	!		EQ 50MG BASE	N211801	001	Sep 12, 2019	Feb CMFD

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

	+	@	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309	002	Sep 07, 2012	Jan DISC
	+	@		1.62% (40.5MG/2.5GM PACKET)	N022309	003	Sep 07, 2012	Jan DISC
	+	@		25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan DISC
	+	@		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan DISC
			TESTOSTERONE					
AB1	!		ACTAVIS LABS UT INC	50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jan CHRS
AB2	!		PADAGIS ISRAEL	1.62% (40.5MG/2.5GM PACKET)	A205781	002	Jul 12, 2017	Jan CHRS

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

>D>	AB	HIKMA	12.5MG	A209739	001	Apr 08, 2019	Feb DISC
>A>		@	12.5MG	A209739	001	Apr 08, 2019	Feb DISC
>D>	AB		25MG	A209739	002	Apr 08, 2019	Feb DISC
>A>		@	25MG	A209739	002	Apr 08, 2019	Feb DISC

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

>A>	AB	AMNEAL	1MG	A215456	001	Feb 28, 2022	Feb NEWA
>A>	AB		2MG	A215456	002	Feb 28, 2022	Feb NEWA
>A>	AB		5MG	A215456	003	Feb 28, 2022	Feb NEWA
>A>	AB		10MG	A215456	004	Feb 28, 2022	Feb NEWA

TICAGRELOR

TABLET;ORAL

BRILINTA

>D>	AB	+ ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Feb CTEC
>A>		+	60MG	N022433	002	Sep 03, 2015	Feb CTEC
>D>		TICAGRELOR					
>D>	AB	MYLAN	60MG	A208597	001	Jul 09, 2021	Feb DISC
>A>		@	60MG	A208597	001	Jul 09, 2021	Feb DISC
>D>	AB		90MG	A208597	002	Jul 09, 2021	Feb DISC
>A>		@	90MG	A208597	002	Jul 09, 2021	Feb DISC

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOPTIC IN OCUDOSE

>D>	AT3	+! BAUSCH	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Feb CAHN
>D>	AT3	+!	EQ 0.5% BASE	N019463	002	Nov 05, 1986	Feb CAHN
>A>	AT3	+! BAUSCH AND LOMB INC	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Feb CAHN
>A>	AT3	+!	EQ 0.5% BASE	N019463	002	Nov 05, 1986	Feb CAHN

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB

@ ZYDUS PHARMS

@

XELJANZ XR

+ PFIZER

+!

			EQ 11MG BASE	A214264	001	Aug 19, 2021	Jan DISC
			EQ 22MG BASE	A214264	002	Aug 19, 2021	Jan DISC
			EQ 11MG BASE	N208246	001	Feb 23, 2016	Jan CTEC
			EQ 22MG BASE	N208246	002	Dec 12, 2019	Jan CTEC

TOLVAPTAN

TABLET;ORAL

SAMSCA

+ OTSUKA

+!

TOLVAPTAN

+ PAR PHARM INC

+!

>D>			15MG	N022275	001	May 19, 2009	Feb CFTG
>A>	AB		15MG	N022275	001	May 19, 2009	Feb CFTG
>A>	AB		15MG	A206119	001	Feb 15, 2022	Feb NFTG
>A>	AB		30MG	A206119	002	Feb 15, 2022	Feb NEWA

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED;NASAL

NASACORT

@ CHATTEM SANOFI

@

FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

ZILRETTA

+! FLEXION THERAPS INC

+! PACIRA PHARMS INC

INJECTABLE;INJECTION

TRIAMCINOLONE ACETONIDE

AB CUSTOPHARM INC

AB LONG GROVE PHARMS

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

@ PERRIGO PHARMA INTL

			0.055MG/INH	N019798	001	Jul 11, 1991	Jan CAHN
			0.055MG/INH	N019798	001	Jul 11, 1991	Jan CAHN
>D>			32MG/VIAL	N208845	001	Oct 06, 2017	Feb CAHN
>A>			32MG/VIAL	N208845	001	Oct 06, 2017	Feb CAHN
			40MG/ML	A213543	001	Jan 19, 2022	Jan NEWA
			40MG/ML	A213543	001	Jan 19, 2022	Jan CAHN
			0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jan CAHN

TROSPIUM CHLORIDETABLET;ORAL  
TROSPIUM CHLORIDE

>A>	AB	AMICI	20MG	A215781	001	Feb 16, 2022	Feb	NEWA
-----	----	-------	------	---------	-----	--------------	-----	------

UPADACITINIBTABLET, EXTENDED RELEASE;ORAL  
RINVOQ

+	ABBVIE INC	15MG	N211675	001	Aug 16, 2019	Jan	CHRS
+	!	30MG	N211675	002	Jan 14, 2022	Jan	NEWA

URSODIOLCAPSULE;ORAL  
URSODIOL

>D>	AB	VGYAAN	300MG	A214329	001	Jul 28, 2021	Feb	DISC
>A>		@	300MG	A214329	001	Jul 28, 2021	Feb	DISC

VALGANCICLOVIR HYDROCHLORIDEFOR SOLUTION;ORAL  
VALGANCICLOVIR HYDROCHLORIDE

>A>	AB	AIRIS PHARMA PVT LTD	50MG/ML	A210169	001	Feb 17, 2022	Feb	NEWA
-----	----	----------------------	---------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDEINJECTABLE;INJECTION  
VANCOCIN HYDROCHLORIDE

@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Jan	CAHN
@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Jan	CAHN
@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Jan	CAHN
@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Jan	CAHN
@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Jan	CAHN
@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Jan	CAHN
@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Jan	CAHN
@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Jan	CAHN
@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Jan	CAHN

>A>	AP	KNACK	EQ 500MG BASE/VIAL	A213059	001	Feb 15, 2022	Feb	NEWA
>A>	AP		EQ 750MG BASE/VIAL	A213059	002	Feb 15, 2022	Feb	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A213059	003	Feb 15, 2022	Feb	NEWA

POWDER;INTRAVENOUS  
VANCOMYCIN HYDROCHLORIDE

>D>		+	MYLAN LABS LTD	EQ 250MG BASE/VIAL	N209481	001	Jul 10, 2018	Feb	DISC
>A>		+	@	EQ 250MG BASE/VIAL	N209481	001	Jul 10, 2018	Feb	DISC

VARDENAFIL HYDROCHLORIDETABLET;ORAL  
LEVITRA

>D>									
>D>	AB	+	BAYER HLTHCARE	EQ 20MG BASE	N021400	004	Aug 19, 2003	Feb	DISC
>A>		+	@	EQ 20MG BASE	N021400	004	Aug 19, 2003	Feb	DISC

VARDENAFIL HYDROCHLORIDE

>D>	AB		ZYDUS PHARMS	EQ 20MG BASE	A208960	004	Oct 31, 2018	Feb	CHRS
>A>	AB	!		EQ 20MG BASE	A208960	004	Oct 31, 2018	Feb	CHRS

VARENICLINE TARTRATETABLET;ORAL  
CHANTIX

>D>	AB	+	PF PRISM CV	EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CHRS
>A>	AB	+		EQ 1MG BASE	N021928	002	May 10, 2006	Feb	CHRS

VARENICLINE TARTRATE

>D>	AB		PAR PHARM INC	EQ 1MG BASE	A201785	002	Aug 11, 2021	Feb	CHRS
>A>	AB	!		EQ 1MG BASE	A201785	002	Aug 11, 2021	Feb	CHRS

VENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
VENLAFAXINE HYDROCHLORIDE

@	YICHANG HUMANWELL	EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Jan	DISC
@		EQ 75MG BASE	A214654	002	Aug 06, 2021	Jan	DISC
@		EQ 150MG BASE	A214654	003	Aug 06, 2021	Jan	DISC

VIGABATRINTABLET; ORAL  
VIGABATRIN

AB	ZYDUS	500MG	A215707	001	Jan 19, 2022	Jan NEWA
----	-------	-------	---------	-----	--------------	----------

ZINC CHLORIDEINJECTABLE; INJECTION  
ZINC CHLORIDE

>D>							
>D>	AP	EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb DISC
>A>		@	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	Feb DISC
		ZINC CHLORIDE IN PLASTIC CONTAINER					
>D>	AP	+! HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Feb CTEC
>A>		+!	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	Feb CTEC

ZIPRASIDONE HYDROCHLORIDECAPSULE; ORAL  
GEODON

AB	+!	VIATRIS	EQ 20MG BASE	N020825	001	Feb 05, 2001	Jan CAHN
AB	+		EQ 40MG BASE	N020825	002	Feb 05, 2001	Jan CAHN
AB	+		EQ 60MG BASE	N020825	003	Feb 05, 2001	Jan CAHN
AB	+		EQ 80MG BASE	N020825	004	Feb 05, 2001	Jan CAHN

ZIPRASIDONE MESYLATEINJECTABLE; INTRAMUSCULAR  
GEODON

>D>								
>D>								
>D>	AP	+!	VIATRIS	EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Feb CDFR
	AP	+!		EQ 20MG BASE/ML	N020919	001	Jun 21, 2002	Jan CAHN
>D>			ZIPRASIDONE MESYLATE					
>D>	AP		GLAND PHARMA LTD	EQ 20MG BASE/ML	A211908	001	Dec 26, 2019	Feb CDFR
>A>			POWDER; INTRAMUSCULAR					
>A>			GEODON					
>A>	AP	+!	VIATRIS	EQ 20MG BASE/VIAL	N020919	001	Jun 21, 2002	Feb CDFR
>A>			ZIPRASIDONE MESYLATE					
>A>	AP		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A211908	001	Dec 26, 2019	Feb CDFR

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

AUROBINDO PHARMA LTD 250MG;250MG;65MG

A211695 001 Feb 02, 2022 Jan NEWA

ADAPALENE

GEL;TOPICAL

ADAPALENE

TARO PHARMS 0.1%

A215940 001 Jan 14, 2022 Jan NEWA

ESOMEPRAZOLE MAGNESIUM

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

+ @ DEXCEL PHARMA EQ 20MG BASE

N214278 001 Oct 20, 2020 Jan DISC

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

VKT PHARMA 10MG

A215822 001 Jan 28, 2022 Jan NEWA

20MG

A215822 002 Jan 28, 2022 Jan NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+! CHATTEM SANOFI 60MG;120MG

N020786 002 Jan 24, 2011 Jan CAHN

+! 60MG;120MG

N020786 002 Jan 24, 2011 Jan CAHN

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+! CHATTEM SANOFI 180MG;240MG

N021704 002 Jan 24, 2011 Jan CAHN

+! 180MG;240MG

N021704 002 Jan 24, 2011 Jan CAHN

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

L PERRIGO CO 600MG;60MG

A214407 001 Feb 01, 2022 Jan NEWA

1.2GM;120MG

A214407 002 Feb 01, 2022 Jan NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI 2.5MG/5ML

N209090 001 Jan 31, 2017 Jan CAHN

TABLET;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI 5MG

N209089 001 Jan 31, 2017 Jan CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

PERRIGO PHARMA INTL 5%

A091344 001 Apr 28, 2011 Jan CAHN

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS &amp; COLD

+ @ BAYER 220MG;120MG

N021076 001 Nov 29, 1999 Jan DISC

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

! PERRIGO 220MG;120MG

A076518 001 Mar 17, 2004 Jan CHRS

OMEPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

&gt;D&gt; + DEXCEL PHARMA 20MG

N209400 001 Jul 05, 2017 Feb CHRS

&gt;A&gt; +! 20MG

N209400 001 Jul 05, 2017 Feb CHRS

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

+ @ ROXANE 1GM/ML

N018551 001 Feb 19, 1982 Jan CRLD

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

ZANTAC 150

+ @ CHATTEM SANOFI EQ 150MG BASE N021698 001 Aug 31, 2004 Jan CAHN

+ @ ZANTAC 150 EQ 150MG BASE N021698 002 Mar 13, 2007 Jan CAHN

ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE N020520 001 Dec 19, 1995 Jan CAHN

TABLET, EFFERVESCENT;ORAL

ZANTAC 75

+ @ CHATTEM SANOFI EQ 75MG BASE N020745 001 Feb 26, 1998 Jan CAHN

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

NASACORT ALLERGY 24 HOUR

+! CHATTEM SANOFI 0.055MG/SPRAY N020468 002 Oct 11, 2013 Jan CAHN

+! 0.055MG/SPRAY N020468 002 Oct 11, 2013 Jan CAHN

TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jan CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 2 FEBRUARY 2022**

NO FEBRUARY 2022 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)



**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO FEBRUARY 2022 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABROCITINIB - CIBINQO</u>						
N 213871 001	>A> 9035074	Feb 19, 2034	DS DP		>A> NCE	Jan 14, 2027
	>A> 9545405	Feb 19, 2034	DS DP			
	>A> 9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 002	>A> 9035074	Feb 19, 2034	DS DP		>A> NCE	Jan 14, 2027
	>A> 9545405	Feb 19, 2034	DS DP			
	>A> 9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 003	>A> 9035074	Feb 19, 2034	DS DP		>A> NCE	Jan 14, 2027
	>A> 9545405	Feb 19, 2034	DS DP			
	>A> 9549929	Feb 19, 2034	U-3195			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	>A> 10004743	Jul 05, 2030	DP		>A> ODE-115	Apr 15, 2023
	>A> 10004743*PED	Jan 05, 2031			>A> ODE-230	Jan 12, 2025
	>A> 8426586	Oct 10, 2029	DS		>A> PED	Oct 15, 2023
	>A> 8426586*PED	Apr 10, 2030			>A> PED	Jul 12, 2025
	>A> 8545884	Dec 19, 2029	DP			
	>A> 8545884*PED	Jun 19, 2030				
	>A> 9539258	Nov 09, 2026	U-1950			
	>A> 9539258*PED	May 09, 2027				
	>A> RE43431	Jan 13, 2026	DS			
	>A> RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	>A> 10004743	Jul 05, 2030	DP		>A> ODE-115	Apr 15, 2023
	>A> 10004743*PED	Jan 05, 2031			>A> ODE-230	Jan 12, 2025
	>A> 8426586	Oct 10, 2029	DS		>A> PED	Oct 15, 2023
	>A> 8426586*PED	Apr 10, 2030			>A> PED	Jul 12, 2025
	>A> 8545884	Dec 19, 2029	DP			
	>A> 8545884*PED	Jun 19, 2030				
	>A> 9539258	Nov 09, 2026	U-1950			
	>A> 9539258*PED	May 09, 2027				
	>A> RE43431	Jan 13, 2026	DS			
	>A> RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	>A> 10004743	Jul 05, 2030	DP		>A> ODE-115	Apr 15, 2023
	>A> 10004743*PED	Jan 05, 2031			>A> ODE-230	Jan 12, 2025
	>A> 8426586	Oct 10, 2029	DS		>A> PED	Oct 15, 2023
	>A> 8426586*PED	Apr 10, 2030			>A> PED	Jul 12, 2025
	>A> 8545884	Dec 19, 2029	DP			
	>A> 8545884*PED	Jun 19, 2030				
	>A> 9539258	Nov 09, 2026	U-1950			
	>A> 9539258*PED	May 09, 2027				
	>A> RE43431	Jan 13, 2026	DS			
	>A> RE43431*PED	Jul 13, 2026				
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11197835	Dec 02, 2030	U-2106			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11197835	Dec 02, 2030	U-2106			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	>A> 11235169	Oct 15, 2040	U-3303			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	10525033	Mar 10, 2031	DP		>A> NCE	Feb 26, 2025
	9084765	Mar 10, 2031	U-1744			
	9084765	Mar 10, 2031	U-2754			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	>A> 11253474	Feb 24, 2041	DP U-3309			
	>A> 11253474	Feb 24, 2041	DP U-3310			
	>A> 11253474	Feb 24, 2041	DP U-3311			
<u>AMPHOTERICIN B - AMPHOTERICIN B</u>						
A 212514 001					>A> CGT	Aug 14, 2022
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>APOMORPHINE HYDROCHLORIDE - APOMORPHINE HYDROCHLORIDE</u>						
A 212025 001					>A> CGT	Aug 24, 2022
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6962940	Mar 19, 2023	U-1504		>A> I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6962940	Mar 19, 2023	U-1504		>A> I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 002	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6962940	Mar 19, 2023	U-1504		>A> I-884	Dec 20, 2024
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001 >A>	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002 >A>	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003 >A>	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004 >A>	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005 >A>	11229378	Jul 11, 2031	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006 >A>	11229378	Jul 11, 2031	DP			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	8829195	May 13, 2033	DS U-1374		ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	8829195	May 13, 2033	DS U-1374		ODE-381 ODE-382	Oct 29, 2028 Oct 29, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVACOPAN - TAVNEOS</u>						
N 214487	001				ODE-377	Oct 07, 2028
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094	001	>A> 11230530	Mar 09, 2035	U-3300		
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094	002	>A> 11230530	Mar 09, 2035	U-3300		
<u>BETAINE - BETAINE</u>						
A 214864	001				CGT	Aug 02, 2022
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251	002				NCE ODE-378	Feb 07, 2023 Oct 07, 2028
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	001	8618109	Apr 12, 2026	U-3281	NPP	Dec 27, 2024
		8618109	Apr 12, 2026	U-543		
		9839637	Apr 12, 2026	DP U-1529		
		9839637	Apr 12, 2026	DP U-3281		
		9839637	Apr 12, 2026	DP U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	002	8618109	Apr 12, 2026	U-3281	NPP	Dec 27, 2024
		8618109	Apr 12, 2026	U-543		
		9839637	Apr 12, 2026	DP U-1529		
		9839637	Apr 12, 2026	DP U-3281		
		9839637	Apr 12, 2026	DP U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	003	8618109	Apr 12, 2026	U-3281	NPP	Dec 27, 2024
		8618109	Apr 12, 2026	U-543		
		9839637	Apr 12, 2026	DP U-1529		
		9839637	Apr 12, 2026	DP U-3281		
		9839637	Apr 12, 2026	DP U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	004	8618109	Apr 12, 2026	U-3281	NPP	Dec 27, 2024
		8618109	Apr 12, 2026	U-543		
		9839637	Apr 12, 2026	DP U-1529		
		9839637	Apr 12, 2026	DP U-3281		
		9839637	Apr 12, 2026	DP U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	005	8618109	Apr 12, 2026	U-3281	NPP	Dec 27, 2024
		8618109	Apr 12, 2026	U-543		
		9839637	Apr 12, 2026	DP U-1529		
		9839637	Apr 12, 2026	DP U-3281		
		9839637	Apr 12, 2026	DP U-543		
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422	006	8618109	Apr 12, 2026	U-3281	NPP	Dec 27, 2024
		8618109	Apr 12, 2026	U-543		
		9839637	Apr 12, 2026	DP U-1529		
		9839637	Apr 12, 2026	DP U-3281		
		9839637	Apr 12, 2026	DP U-543		
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398	001	7323463	Jan 19, 2023	DP	Y	
<u>BUDESONIDE - TARPEYO</u>						
N 215935	001				NP	Dec 15, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	>A> 11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	>A> 11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	>A> 11253504	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	>A> 11253504	Mar 13, 2034	U-3118			
<u>CABOTEGRAVIR - APRETUDE</u>						
N 215499 001	10927129	Apr 28, 2026	DS DP		>A> NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	>A> 11224597	Sep 15, 2031	DP U-3060			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	>A> 11224597	Sep 15, 2031	DP U-3060			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	>A> 11253528	Mar 14, 2034	DP			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	11207292	Apr 26, 2039	DS	U-3235		
	11207292	Apr 26, 2039	DS	U-3236		
	11207292	Apr 26, 2039	DS	U-3277		
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	>A> 11033521	Mar 28, 2039	DP U-219			
	>A> 11033521	Mar 28, 2039	DP U-3304			
	>A> 11033521	Mar 28, 2039	DP U-3305			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2023	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	11207332	Nov 20, 2028	DP U-3280			
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	11129896	Sep 22, 2036	U-3293		NP GAIN	Dec 07, 2024 Dec 07, 2029
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
<u>DAPTOMYCIN - DAPZURA RT</u>						
N 213645 001	11173189	Mar 11, 2041	DP U-3294			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11168058	Feb 27, 2038	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001 >A>	11236328	Jun 22, 2032	U-3301			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	11179386	Mar 15, 2038	DP U-1995			
	11179386	Mar 15, 2038	DP U-3055			
	11179386*PED	Sep 15, 2038				
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001 >A>	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002 >A>	11241414	Mar 27, 2029	DP			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003 >A>	11241414	Mar 27, 2029	DP			
<u>DIGOXIN - DIGOXIN</u>						
A 214982 001				>A> CGT		Aug 16, 2022
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001 >A>	11234985	Jan 24, 2031	DP U-257			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001 >A>	8486975	Oct 07, 2031	DS DP U-2394			
	>A> 8486975	Oct 07, 2031	DS DP U-2630			
	>A> 8486975	Oct 07, 2031	DS DP U-3308			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001 >A>	8486975	Oct 07, 2031	DS DP U-2395			
	>A> 8486975	Oct 07, 2031	DS DP U-2629			
	>A> 8486975	Oct 07, 2031	DS DP U-3307			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001 >A>	11234954	Jan 18, 2028	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002 >A>	11234954	Jan 18, 2028	U-620			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001 >A>	11253472	Aug 06, 2028	DS DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	11202772	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	11202772	Apr 13, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	11202772	Apr 13, 2037	DP			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	11213519	Jan 03, 2028	U-2720			
<u>ELBASVIR; GRAZOPREVIR - ZEPATIER</u>						
N 208261 001					NPP	Dec 09, 2024
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1736			
	>A> 7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	>A> 11229627	Mar 14, 2033	DP			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	>A> 11229627	Mar 14, 2033	DP			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	8754065	Aug 15, 2032	DS DP		U-1663	
	9296769	Aug 15, 2032	DS DP		U-1663	
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	11173141	Mar 25, 2036	DP			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	9474754	Aug 05, 2033	U-2802			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	>A> 11241400	May 16, 2040	U-3183			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	10961190	Oct 19, 2037	DS			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	10961190	Oct 19, 2037	DS			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	>A> 11241445	Nov 21, 2032	U-2316			
	>A> 11241445	Nov 21, 2032	U-2317			
	>A> 11246875	Nov 21, 2032	U-2316			
	>A> 11246875	Nov 21, 2032	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	>A> 11241445	Nov 21, 2032	U-2316			
	>A> 11241445	Nov 21, 2032	U-2317			
	>A> 11246875	Nov 21, 2032	U-2316			
	>A> 11246875	Nov 21, 2032	U-2317			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 001	>A> 11123321	Oct 20, 2023	DS DP U-2555			
	>A> 11123321	Oct 20, 2023	DS DP U-2557			
	>A> 11123321	Oct 20, 2023	DS DP U-3312			
	>A> 11123321	Oct 20, 2023	DS DP U-3313			
	>A> 7754702	Feb 15, 2028	U-1432			
	>A> 7754702	Feb 15, 2028	U-2555			
	>A> 7754702	Feb 15, 2028	U-2556			
	>A> 7754702	Feb 15, 2028	U-2557			
	>A> 7754702	Feb 15, 2028	U-3312			
	>A> 7754702	Feb 15, 2028	U-3313			
	>A> 7754702	Feb 15, 2028	U-3314			
	>A> 8895612	Jan 08, 2027	U-1620			
	>A> 8895612	Jan 08, 2027	U-3050			
	>A> 8895612	Jan 08, 2027	U-3051			
	>A> 8895612	Jan 08, 2027	U-3115			
	>A> 8895612	Jan 08, 2027	U-3116			
	>A> 8895612	Jan 08, 2027	U-3315			
	>A> 8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 002	>A> 11123321	Oct 20, 2023	DS DP U-2555			
	>A> 11123321	Oct 20, 2023	DS DP U-2557			
	>A> 11123321	Oct 20, 2023	DS DP U-3312			
	>A> 11123321	Oct 20, 2023	DS DP U-3313			
	>A> 7754702	Feb 15, 2028	U-2555			
	>A> 7754702	Feb 15, 2028	U-2556			
	>A> 7754702	Feb 15, 2028	U-2557			
	>A> 7754702	Feb 15, 2028	U-3312			
	>A> 7754702	Feb 15, 2028	U-3313			
	>A> 7754702	Feb 15, 2028	U-3314			
	>A> 8895612	Jan 08, 2027	U-1620			
	>A> 8895612	Jan 08, 2027	U-3050			
	>A> 8895612	Jan 08, 2027	U-3051			
	>A> 8895612	Jan 08, 2027	U-3115			
	>A> 8895612	Jan 08, 2027	U-3116			
	>A> 8895612	Jan 08, 2027	U-3315			
	>A> 8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 003	>A> 11123321	Oct 20, 2023	DS DP U-2555			
	>A> 11123321	Oct 20, 2023	DS DP U-2557			
	>A> 11123321	Oct 20, 2023	DS DP U-3312			
	>A> 11123321	Oct 20, 2023	DS DP U-3313			
	>A> 7754702	Feb 15, 2028	U-2555			
	>A> 7754702	Feb 15, 2028	U-2556			
	>A> 7754702	Feb 15, 2028	U-2557			
	>A> 7754702	Feb 15, 2028	U-3312			
	>A> 7754702	Feb 15, 2028	U-3313			
	>A> 7754702	Feb 15, 2028	U-3314			
	>A> 8895612	Jan 08, 2027	U-1620			
	>A> 8895612	Jan 08, 2027	U-3050			
	>A> 8895612	Jan 08, 2027	U-3051			
	>A> 8895612	Jan 08, 2027	U-3115			
	>A> 8895612	Jan 08, 2027	U-3116			
	>A> 8895612	Jan 08, 2027	U-3315			
	>A> 8895612	Jan 08, 2027	U-3316			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 004	>A> 11123321	Oct 20, 2023	DS DP U-3312			
	>A> 11123321	Oct 20, 2023	DS DP U-3313			
	>A> 7612109	Feb 05, 2024	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	>A> 7754702	Feb 15, 2028	U-3312			
	>A> 7754702	Feb 15, 2028	U-3313			
	>A> 7754702	Feb 15, 2028	U-3314			
	>A> 8895612	Jan 08, 2027	U-3115			
	>A> 8895612	Jan 08, 2027	U-3116			
	>A> 8895612	Jan 08, 2027	U-3315			
	>A> 8895612	Jan 08, 2027	U-3316			
	>A> 9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	>A> 11234938	Nov 26, 2034	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	>A> RE48898	Jan 19, 2026	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	>A> RE48898	Jan 19, 2026	DP			
<u>GALLIUM GA-68 GOZETOTIDE - ILLUCCIX</u>						
N 214032 001	>A> 11027031	Jul 28, 2035	U-3317			
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	>A> 11028392	Oct 03, 2034	DS DP U-2672			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	>A> 11246866	Jun 24, 2036	DP			
	>A> 11246866*PED	Dec 24, 2036				
	>A> RE48923	May 08, 2035	DS			
	>A> RE48923*PED	Nov 08, 2035				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	>A> RE48923	May 08, 2035	DS			
	>A> RE48923*PED	Nov 08, 2035				
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566 001					NPP	Aug 18, 2024
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	>A> 11235168	Jan 04, 2038	U-2250			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	11213504	Apr 29, 2030	U-3292			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	11213504	Apr 29, 2030	U-3292			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
<u>INCLISIRAN SODIUM - LEQVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			
	10273477	Mar 08, 2024	DS			
	10590418	Jul 19, 2022	U-3272			
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-3272			
	11078485	Nov 04, 2023	DS U-3272			
	8106022	Dec 12, 2029	DS DP U-3272			
	8222222	Dec 29, 2027	U-3272			
	8232383	Feb 20, 2023	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	8546143	Apr 23, 2022	DS U-3272			
	8809292	May 10, 2027	DS DP U-3272			
	8828956	Dec 04, 2028	DS DP U-3272			
	9074213	Mar 09, 2022	DS U-3272			
	9370582	Dec 04, 2028	DS DP U-3272			
	9708610	Jan 01, 2024	DS DP U-3272			
	9708615	Mar 08, 2024	DS			
<u>ISOSORBIDE DINITRATE - ISOSORBIDE DINITRATE</u>						
A 211290 001					>A> CGT	Jun 20, 2022
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001					NPP	Oct 14, 2024
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 001					>A> PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 002					>A> PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 003					>A> PC	Aug 30, 2022
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 201452 004					>A> PC	Aug 30, 2022
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001					NPP	Dec 10, 2024
<u>LEVOKETONAZOLE - RECORLEV</u>						
N 214133 001	10098877	Jan 10, 2026	U-3283			
	10517868	Jan 10, 2026	U-3283			
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	9918984	Jan 10, 2026	U-3283			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11219596	May 03, 2033	U-2985			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	11026951	Dec 03, 2034	U-3274			
	RE48839	Dec 28, 2029	U-3271			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	RE48839	Dec 28, 2029	U-814			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	11229647	Feb 12, 2040	U-3290		ODE-379	Sep 29, 2028
	>A> 11260053	May 26, 2031	U-3290			
<u>MARAVIROC - MARAVIROC</u>						
A 203347 001					>A> PC	Aug 06, 2022
<u>MARAVIROC - MARAVIROC</u>						
A 203347 002					>A> PC	Aug 06, 2022
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001					NCE	Nov 23, 2026
<u>MELOXICAM - ANJESO</u>						
N 210583 001	>A> 11253478	May 26, 2030	DP U-3318			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	>A> 11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	>A> 11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	>A> 11166947	Jan 25, 2038	U-3299			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	>A> 11241391	Mar 23, 2032	U-2357			
	>A> 11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	>A> 11241391	Mar 23, 2032	U-2357			
	>A> 11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	>A> 11241391	Mar 23, 2032	U-2357			
	>A> 11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	>A> 11241391	Mar 23, 2032	U-2357			
	>A> 11241392	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	>A> 11241391	Mar 23, 2032	U-2357			
	>A> 11241392	Mar 23, 2032	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	>A> 11234972	Mar 15, 2037	U-2371			
	>A> 11241422	May 16, 2027	U-2371			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	>A> 10632114	May 03, 2032	U-3320			
	>A> 11234976	Oct 11, 2038	U-3321			
	>A> 11254652	Nov 21, 2038	DS DP			
	>A> 8785450	Feb 24, 2031	DS DP			
	>A> 9193701	Oct 26, 2032	U-3319			
	>A> 9682080	May 03, 2032	U-3319			
	>A> 9980961	May 03, 2032	U-3319			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	>A> 10632114	May 03, 2032	U-3320			
	>A> 11234976	Oct 11, 2038	U-3321			
	>A> 11254652	Nov 21, 2038	DS DP			
	>A> 8785450	Feb 24, 2031	DS DP			
	>A> 9193701	Oct 26, 2032	U-3319			
	>A> 9682080	May 03, 2032	U-3319			
	>A> 9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	>A> 10632114	May 03, 2032	U-3320			
	>A> 11234976	Oct 11, 2038	U-3321			
	>A> 11254652	Nov 21, 2038	DS DP			
	>A> 8785450	Feb 24, 2031	DS DP			
	>A> 9193701	Oct 26, 2032	U-3319			
	>A> 9682080	May 03, 2032	U-3319			
	>A> 9980961	May 03, 2032	U-3319			
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	>A> 10016443	Sep 04, 2034	U-3297			
	>A> 10376526	Sep 04, 2034	DP			
	>A> 10517880	Sep 04, 2034	DP U-3297			
	>A> 10548907	Sep 04, 2034	U-3297			
	>A> 10561672	Sep 04, 2034	DP			
	>A> 10646500	Sep 04, 2034	U-3297			
	>A> 10758550	Sep 04, 2034	U-3296			
	>A> 10765686	Sep 04, 2034	U-3295			
	>A> 9078923	Sep 04, 2034	DP U-3297			
	>A> 9370483	Sep 04, 2034	DP			
	>A> 9750754	Sep 04, 2034	DP U-3297			
	>A> 9937189	Sep 04, 2034	DP			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003					ODE-380 PED	Sep 23, 2028 Mar 23, 2029
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	11207306	Apr 16, 2038	U-2804			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	>A> RE48286	Feb 21, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	>A> RE48286	Feb 21, 2027	DS DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	>A> 11241425	Aug 23, 2031	U-3137			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	>A> 11241425	Aug 23, 2031	U-3137			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	>A> 11241425	Aug 23, 2031	U-3137			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	>A> 11241425	Aug 23, 2031	U-3137			
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291			
	9061057	Aug 26, 2033	DS DP U-3291			
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP U-3291			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					I-881	Jun 17, 2024
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001					I-881	Jun 17, 2024
<u>REMEDSIVIR - VEKLURY</u>						
N 214787 001	>A> 10695361	Sep 16, 2036	U-2984		>A> D-183	Jan 21, 2025
	>A> 10695361	Sep 16, 2036	U-3249			
	>A> 11007208	Sep 16, 2036	U-2984			
	>A> 11007208	Sep 16, 2036	U-3249			
<u>REMEDSIVIR - VEKLURY</u>						
N 214787 002	>A> 10695361	Sep 16, 2036	U-2984		>A> D-183	Jan 21, 2025
	>A> 10695361	Sep 16, 2036	U-3249			
	>A> 11007208	Sep 16, 2036	U-2984			
	>A> 11007208	Sep 16, 2036	U-3249			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	>A> 11247969	Mar 10, 2025	DP			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001					NPP	Dec 10, 2024
<u>RIOCIQUAT - ADEMPAS</u>						
N 204819 001	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIQUAT - ADEMPAS</u>						
N 204819 002	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIQUAT - ADEMPAS</u>						
N 204819 003	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIQUAT - ADEMPAS</u>						
N 204819 004	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIOCIQUAT - ADEMPAS</u>						
N 204819 005	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP		NP PED	Dec 20, 2024 Jun 20, 2025
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	11219624	May 20, 2031	DP U-3229			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	>A> 10335390	Sep 04, 2035	DP U-2583		>A> NPP	Jan 26, 2025
	>A> 10335390	Sep 04, 2035	DP U-3270			
	>A> 10682338	Sep 04, 2035	DP U-2583			
	>A> 10682338	Sep 04, 2035	DP U-3270			
	>A> 10849884	Sep 04, 2035	DP U-2583			
	>A> 10849884	Sep 04, 2035	DP U-3169			
	>A> 10849884	Sep 04, 2035	DP U-3270			
	>A> 10849884	Sep 04, 2035	DP U-3302			
	>A> 10857133	Sep 04, 2035	DP U-2583			
	>A> 10857133	Sep 04, 2035	DP U-3270			
	>A> 11000507	Sep 04, 2035	DP U-2583			
	>A> 11000507	Sep 04, 2035	DP U-3169			
	>A> 11000507	Sep 04, 2035	DP U-3270			
	>A> 11000507	Sep 04, 2035	DP U-3302			
	>A> 11000508	Sep 04, 2035	DP U-2583			
	>A> 11000508	Sep 04, 2035	DP U-3169			
	>A> 11000508	Sep 04, 2035	DP U-3270			
	>A> 11000508	Sep 04, 2035	DP U-3302			
	>A> 11020377	Sep 04, 2035	DP U-2583			
	>A> 11020377	Sep 04, 2035	DP U-3169			
	>A> 11020377	Sep 04, 2035	DP U-3270			
	>A> 11020377	Sep 04, 2035	DP U-3302			
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001					ODE* PED	Apr 07, 2024 Oct 07, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480	002				ODE* PED	Apr 07, 2024 Oct 07, 2024
<u>SOTORASIB - LUMAKRAS</u>						
N 214665	001	>A> 10519146	May 21, 2038	DS DP		
		>A> 11236091	May 20, 2040	DS DP U-3306		
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592	001				>A> CGT	Aug 25, 2022
<u>TIMOLOL MALEATE - TIMOLOL MALEATE</u>						
A 212592	002				>A> CGT	Aug 25, 2022
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904	001	>A> 6821987	Apr 26, 2023	DS DP U-3100		
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904	002	>A> 6821987	Apr 26, 2023	DS DP U-3100		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001				I-879	Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	002				I-879	Dec 14, 2024
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	001				I-879	Dec 14, 2024
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474	001				>A> M-271	Jun 24, 2024
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176	001	10981919	Jul 02, 2033	U-3063		
		10981919	Jul 02, 2033	U-3064		
<u>UPADACITINIB - RINVOO</u>						
N 211675	001	>A> 10995095	Oct 17, 2036	U-3298	I-880	Dec 14, 2024
		8962629	Jan 15, 2031	DS U-3255	>A> I-883	Jan 14, 2025
		8962629	Jan 15, 2031	DS U-3275		
<u>UPADACITINIB - RINVOO</u>						
N 211675	002	>A> 10344036	Oct 17, 2036	DP	>A> I-883	Jan 14, 2025
		>A> 10550126	Oct 17, 2036	U-3298	>A> NCE	Aug 16, 2024
		>A> 10730883	Oct 17, 2036	DP		
		>A> 10981923	Oct 17, 2036	DS		
		>A> 10981924	Oct 17, 2036	DP		
		>A> 11186584	Oct 17, 2036	DS		
		>A> 11198697	Oct 17, 2036	DP		
		>A> 8962629	Jan 15, 2031	DS		
		>A> 9951080	Oct 17, 2036	DS DP		
		>A> RE47221	Dec 01, 2030	DS		
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978	001	11224598	Oct 19, 2035	U-1900		
<u>VASOPRESSIN - VASOPRESSIN</u>						
A 211538	001				>A> PC	Jul 17, 2022
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	005	10010575	Jan 30, 2035	U-1857		
		9919026	Jan 30, 2035	DP		
		9925233	Jan 30, 2035	U-1857		
		9925234	Jan 30, 2035	U-1857		



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 02 - February 2022

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036		U-3133		
	11020382	Dec 02, 2036		U-3134		
	9018210	Dec 28, 2032	DS DP			
	9248199	Jan 29, 2034		U-2676		
	9248199	Jan 29, 2034		U-2715		
	9447071	Feb 06, 2035	DS DP			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001					>A> M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002					>A> M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003					>A> M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004					>A> M-232	Jan 28, 2025

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 42<sup>ND</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)